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Abstract

An emerging hypothesis in Parkinson’s disease (PD) is that dopaminergic (DA)
neurons degenerate through a “dying back” axonopathy wherein degeneration begins in
the distal axon and progresses over time towards the cell body. Impaired axonal
transport also appears to play an early, pivotal role in PD. Thus processes that delay
axonal transport dysfunction and/or axonal degeneration might slow PD progression.
Previously, we and others have found that the WldS mouse mutant (“Wallerian
degeneration-slow”), which exhibits delayed axonal degeneration after peripheral
axonopathy, also protects DA terminal fields from the PD-mimetics 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) in vivo. To
understand the mechanisms underlying WldS-mediated axonal protection, we tested
whether WldS rescued DA neurons in vitro after treatment with either MPP+, the active
component of MPTP, or 6-OHDA. WldS, but not its component parts, UbE4b and
Nmnat1, robustly rescued neurites in dissociated DA cultures following either MPP+ or 6OHDA treatment. To extend these results, compartmented chambers were developed
such that axons could be segregated from cell bodies and dendrites. Using these
devices, we found that MPP+ impaired mitochondrial, but not synaptic vesicle transport,
in DA axons and that WldS rescued MPP+-mediated impairment of mitochondrial
transport in DA axons. Mechanistically, this appears to be due to WldS-mediated
protection from toxin-induced loss of mitochondrial membrane potential. These results
extend WldS protection to CNS DA neurons and suggest that WldS confers a gain-offunction phenotype that attenuates mitochondrial dysfunction. This study, together with
the large amount of evidence suggesting PD is associated with axonal “dying-back”, also
underscores the necessity of developing therapeutics aimed at axons as well as cell
bodies so as to preserve circuitry and function.
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Chapter 1

Introduction
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1.1

Parkinson’s disease: Overview
Parkinson’s disease (PD) is the second most common neurodegenerative

disease in the United States. Presenting late in life, it affects 1% of the population
over the age of 55. This progressive neurodegenerative disease is characterized
by the loss of dopaminergic neurons in the substantia nigra (SN) which project to
the striatum [1-2].

PD is also associated with the formation of cytoplasmic

inclusions in the nervous system called Lewy bodies. Lewy bodies are spherical
eosinophilic aggregates composed of proteins such as α-synuclein, parkin, and
ubiquitin [4].

Striatal dopamine (DA) deficiency results in diminished motor

control in PD, characterized by resting tremor, rigidity, bradykinesia and postural
instability [5-6]. These motor symptoms do not appear until there is
approximately a 30% loss of DA neurons and about 50-60% loss of DA [7].
Although positron emission tomography (PET) imaging shows decreased
fluorodopa uptake in the striatum indicating a loss of DA innervation, the clinical
diagnosis of PD can only be confirmed by post-mortem pathology.
PD-related neurodegeneration extends beyond the DA neurons of the SN.
It is evident in noradrenergic [8], serotonergic [9], and cholinergic systems [10] as
well as the cerebral cortex, olfactory bulb and autonomic nervous system [5]. In
fact, the earliest pathology of PD is the presence of thread-like inclusion bodies,
or Lewy neurites, in the axons of peripheral neurons [5]. Moreover, degeneration
of hippocampal structures and cholinergic inputs to the cortex have been known
to contribute to the comorbidity of dementia in PD [11].
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At present, there is no known cure for PD. Current treatments target
replenishment of striatal DA via administration of the DA precursor, levodopa,
which initially alleviates most of the symptoms of PD. However, this treatment
does not prevent or slow the progression of the disease. It often produces severe
dyskinetic side effects and may decrease in efficacy throughout disease
progression [12]. The etiology of PD is still unknown, but much about PD has
been learned from epidemiological studies, post-mortem studies, and animal
model systems.

1.2

Genetic factors
Genetic studies of individuals with familial PD have led to the identification

of fifteen loci (PARK1-15) that are linked to PD [13]. Genes associated with the
disease at eleven of these loci have been identified: α-synuclein, Parkin, αsynuclein duplications and triplications, ubiquitin C-terminal hydrolase L1 (UCHL1), PTEN-induced putative kinase 1 (PINK1), DJ-1, leucine-rich repeat kinase 2
(LRRK2), ATP13A2, Omi/HtrA2, PLA2G6, and FBXO7. Although the majority of
PD cases are idiopathic, studies on mutations in the α-synuclein, Parkin, PINK1,
and LRRK2 genes that lead to familial PD have given clues to the molecular
mechanisms that result in DA cell loss in PD.

3

1.2.1 -synuclein
Missense mutations in the gene encoding α-synuclein (A53T, A30P and
E46K) and triplications of a portion of α-synuclein have been linked to autosomal
dominant PD [14-18]. α-synuclein is a presynaptic protein of unknown function,
but is abundant in the brain and associated with vesicles and membranes. Thus,
it is thought to be involved in synaptic vesicle trafficking, storage and
compartmentalization of neurotransmitters [19-22], perhaps as a co-chaperone
[18]. Because α-synuclein tends to aggregate, it has been implicated in PD
pathogenesis. This is consistent with studies showing that α-synuclein is the
major fibrillar component of Lewy bodies in both familial and sporadic PD [4].

1.2.2 LRRK2
Mutations in LRRK2 are the most common known cause of late-onset
autosomal dominant PD and are seen in idiopathic cases of PD [23-25]. LRRK2
is a multi-domain protein that contains a Rho/Ras-like GTPase domain, a
MAPKKK kinase domain, a WD40-repeat domain, a leucine-rich repeat domain,
and a C-terminal of RAS domain. LRRK2 is expressed in forebrain structures
including nigrostriatal DA neurons and localizes to the Golgi, synaptic vesicles,
plasma membrane, lysosomes and outer mitochondrial membranes [26-31].
Although the function of LRRK2 is unknown, deletion of the LRRK2 homolog,
LRK-1, in C. elegans leads to depletion of synaptic vesicle proteins [32]. LRRK2
has also been shown to associate with lipid rafts, localize to Lewy bodies and
4

regulate neurite length and branching [33-35]. The G2019S and I2020T
mutations are located in the kinase domain and are associated with increased
kinase activity [36-39]. Many studies have shown that alterations in the kinase
activity of LRRK2 due to disease-linked mutations affect apoptosis and
neurodegeneration; however it is unclear how these changes in kinase activity
lead to PD [38-40].

1.2.3 Parkin
A loss-of-function mutation in the parkin gene was identified at the PARK2
locus and linked to autosomal recessive juvenile parkinsonism (AR-JP) [41].
Mutations in Parkin are one of the most common known genetic causes of earlyonset PD. Parkin is an E3 ubiquitin-protein ligase that acts in conjunction with E2
ubiquitin-conjugating enzymes to target proteins for degradation via the
proteasome by adding ubiquitin chains to specific substrates [42-44]. Mutations
associated with AR-JP disrupt the E3 ligase activity of parkin, preventing the
targeting of specific proteins to the proteasome. Parkin is neuroprotective against
a variety of toxic insults in DA neurons [45]. Post-translation modifications of
parkin by oxidative stress can inhibit its protective function by impairing its E3
ligase activity [46-47]. Recent data suggests that Parkin is neuroprotective
through its action on mitochondria. Data from Drosophila and mammalian
neuronal cell lines indicates that Parkin is recruited to the mitochondria following
the loss of its membrane potential (m) in response to various toxic insults.
Relocated Parkin serves as a signal for the induction of mitophagy, suggesting
5

that loss of Parkin activity allows the accumulation of dysfunctional mitochondria
that leads to neuron loss in PD [48]. Therefore, another role of Parkin may be to
monitor activity and maintain mitochondrial fidelity by triggering mitophagy if
necessary.

1.2.4 PINK1
Loss-of-function mutations in PINK1 cause autosomal recessive early
onset PD and are found in rare sporadic early onset cases [49-50]. PINK1 is a
serine/threonine kinase that localizes to the mitochondrial intermembrane space
and membranes of the mitochondria [49]. PINK1 is thought to play a role in cell
death pathways as wild-type PINK1 can protect against staurosporine-induced
cytochrome-c release but PD-linked mutations do not. [51]. Data suggest that
PINK1’s kinase activity may play a role in mitochondrial biogenesis and function
[52-53]. In flies, loss of PINK1 by siRNA causes mitochondrial dysfunction and
DA cell loss which is rescued by overexpression of Parkin [54-56], suggesting
that PINK1 is upstream of Parkin. Due to its high turnover rate, PINK1 is normally
present at only low levels on bioenergetically active mitochondria. Mitochondrial
depolarization leads to PINK1’s stabilization and accumulation on mitochondria.
In turn, PINK1 accumulation appears to recruit Parkin to mitochondria in various
cell lines inducing mitophagy. So PINK1 may also protect DA neurons by
activating the removal of damaged mitochondria [57].

6

1.3

Toxin Models
Epidemiological data on PD suggests that various environmental toxins

may also play a role in the etiology of the disease. A number of Parkinsonian
mimetics

have

been

identified,

of

which,

1-methyl-4-phenyl-1,2,3,6-

tetrahydropyridine (MPTP) or its active metabolite spell out

(MPP+) and 6-

hydroxydopamine (6-OHDA) are the two most commonly used. Each of these
toxins has been shown to recapitulate, many, but not all, of the behavioral,
pharmacological, and pathological hallmarks that characterize PD.

1.3.1 MPTP and MPP+
MPTP, a meperidine analog, mimics both the motor deficits and pathology
characteristic of PD in humans [58-59]. Accidental ingestion of MPTP by humans
led to motor deficits characteristic of PD. Similar to PD patients, these patients
responded to L-DOPA treatment and DA agonist therapy [59]. Autopsy on one
patient confirmed severe loss of DA neurons in the SN, but a noticeable lack of
Lewy bodies, in comparison to what is seen in bona fide PD [58].
Administration of MPTP to non-human primates and rodents also
produces PD-like symptoms which respond positively to L-DOPA and selective
DA loss [60]. There is specific loss of DA neurons in the SN with a more dramatic
reduction of striatal axons and DA levels that persist following MPTP exposure in
mice [61-62]. Cytoplasmic inclusions have been shown to develop in MPTPtreated primates [63], although traditional Lewy bodies have not been described
7

[64]. A robust inflammatory response has been shown, including chronic
microgliosis and astrocytosis, which contributes to DA cell loss, as microglial
inhibition protects DA neurons following MPTP administration in rodents [65].
MPTP is able to cross the blood-brain barrier and is rapidly converted to
MPP+ by monoamine oxidase B (MAOB) in glial cells [66]. Despite expression of
MAOB and production of MPP+ in non-DA neurons, MPP+ toxicity is specific to
catecholaminergic neurons because of its high affinity for the DA plasma
membrane transporter (DAT) and other catecholamine uptake systems. In in vitro
systems, direct application of MPP+ induces cell death specifically in DA neurons.
Inside the cell, MPP+ is sequestered into vesicles by the vesicular monoamine
transporter (VMAT2), displacing DA [67]. MPP+ that is not sequestered into
vesicles can enter mitochondria where it inhibits complex I of the electron
transport chain. This leads to ATP depletion, generation of reactive oxygen
species (ROS) and cell death [1, 68].

1.3.2 6-OHDA
6-OHDA is a neurotoxin formed from the auto-oxidation of DA and is found
endogenously in the nigrostriatal pathway [69]. 6-OHDA was the first toxin used
in an animal model to study neurodegeneration in PD [70]. Since 6-OHDA cannot
cross the blood-brain barrier, experimental models of PD require that it is
stereotactically injected into the striatum, the SN or the medial forebrain bundle
(MFB). Similar to MPTP, rodent models utilizing 6-OHDA also lead to depletion of
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striatal DA and degeneration of striatal nerve terminals followed by retrograde
degeneration of neurons in the SN [71]
The specificity of 6-OHDA in vivo towards catecholaminergic cells is due
to its structural similarity to DA and norepinephrine. 6-OHDA is taken up by
catecholaminergic neurons specifically by the DAT and noradrenergic transporter
[72]. Once uptake into DA nerve terminals occurs, 6-OHDA accumulates in the
cytosol and generates ROS by conversion into hydroxyl radicals and 6-OHDA
quinone [73]. Inhibition of 6-OHDA uptake by catecholamine uptake inhibitors
blocks 6-OHDA-induced toxicity in vivo [74]. 6-OHDA also induces cell death in
primary mesencephalic cultures; however, because it is readily oxidized to
hydrogen peroxide in tissue culture buffers, 6-OHDA is not selective for DA
neurons in vitro [75].
6-OHDA inhibits mitochondrial complex I in cell-free assays [76]. However,
in whole cells, 6-OHDA does not cause ATP depletion [77], suggesting that this
is not its main mechanism of action. 6-OHDA induces a collapse in m in
primary DA cultures that is dependent on ROS [78] and p53 [79]. 6-OHDA
treatment also causes release of cytochrome C, activation of caspase 3, DNA
fragmentation [80] and damage [79], and annexin V staining [78], consistent with
an apoptotic type of cell death.

9

1.4

Axonal dysfunction in PD
Although the molecular mechanisms underlying the etiology of PD remain

unclear, the genetic factors and toxin models previously discussed support the
contention that four possibly interchangeable mechanisms underlie PD. These
include: (1) death via impairment of the ubiquitin proteasome system (UPS),
wherein increased levels of misfolded proteins overwhelm the UPS and
accumulate as aggregates in the neuron; (2) death via impairment of
mitochondrial function, specifically, inhibition of mitochondrial complex I leading
to decreased ATP levels and increased levels of ROS; (3) death via oxidative
stress due to internal DA autooxidation, mitochondrial dysfunction, or external
oxidative stresses, and (4) neuroinflammation. Although all of these models may
be true for the death of DA cell bodies, a new emerging hypothesis regarding DA
dysfunction is based on the “dying-back” pattern of neuronal degeneration seen
in PD models. In this model, axonal degeneration begins distally and progresses
proximally over a period of time. This model hypothesizes that the initial insult in
PD occurs at the level of the axon, rather than at the cell body.

1.4.1 Post-mortem PD patient data
Initial support for this hypothesis comes from studies on post-mortem PD
patient brains. As described, Braak et al. have reported that the earliest
pathology of PD is the presence of Lewy neurites in the dorsal motor nucleus and
preganglionic axons of the vagal nerve [5]. These data suggest that the axonal
10

compartment is affected very early in the disease process. By observing patterns
of -synuclein pathology and tyrosine hydroxylase (TH) immunostaining in the
cardiac sympathetic axons and ganglia of PD patients, Orimo et al. proposed that
the PD disease process begins in the distal axon and proceeds retrogradely [81].
In the DA system, dystrophic neurites have been described in the caudate
nucleus of post-mortem brains from PD patients [82]. In addition, multiple studies
done on postmortem brains of PD patients have observed an 80% loss of
putamenal DA [6] and a 68-82% decrease in DA levels in the caudate of PD
patients [83] with only a corresponding 30% cell death in SN neurons [84-86] at
the time of onset of PD motor symptoms. Although postmortem studies may be
subject to misinterpretation due to the effects of postmortem delay, measurement
of another DA marker, VMAT binding, in postmortem caudate of PD patients and
controls led Scherman et al. to conclude that PD motor signs become apparent
when there is about a 50% decrease in VMAT binding relative to age-matched
controls [85]. Consequently, either study revealed significantly more loss of
nigrostriatal terminal field markers compared to the loss of SN DA neurons in PD.
Taken together, the patient data suggest that the initial insult in PD occurs at the
axon versus the cell body.

1.4.2 Functional imaging data
Numerous studies have also examined the relationship between DA
terminal loss and the onset of PD symptoms using radioligand imaging. Three
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types of PET radioligands have been used to assess striatal degeneration: (1)
18F-dopa to assess L-dopa metabolism, (2) ligands to assess DAT binding, and
(3) ligands to assess VMAT2 binding [87]. A 20-50% decrease in putamenal DA
has been reported with 18F-dopa [88-91], while a 50-70% decrease in putamenal
DA was seen using ligands for either DAT or VMAT2 [90, 92-93]. The
discrepancy between neurotransmitter levels versus transporter levels may be
due to a compensatory upregulation of aromatic acid decarboxylase resulting in
the underestimation of terminal losses by 18F-dopa PET [87, 90]. But the 5070% striatal DA loss measured by DAT or VMAT radioligands is consistent with
the 50% striatal DA loss seen in postmortem studies. In addition, both sets of
data show a greater decrease of striatal DA versus the 30% loss of DA neurons
seen in the SN at disease symptom onset. Hence, functional imaging data
provide further support for the idea that degeneration of the axon plays an
important role in the pathogenesis of the disease.

1.4.3 Genetic studies
Early evidence for axonal degeneration is also apparent in several PDlinked gene models. For example, post mortem studies of patients with an synuclein gene triplication reveal widespread and severe neuritic pathology [94].
Dystrophic neurites are also evident in transgenic mice and primate models that
overexpress -synuclein [95-96]. Transgenic mice exhibiting the mutant synuclein gene associated with familial PD (A53T) exhibit intra-axonal
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accumulation of a-synuclein aggregates, vesicles, mitochondria, vacuoles and
neurofilaments, suggesting an interruption of axonal transport and, subsequently,
axonal degeneration [97-98]. Moreover, overexpression of -synuclein causes
neurite degeneration in primary neuronal cultures [99] as well as defective axonal
transport [100]. The latter may be due to the reported association of -synuclein
with complexes containing the molecular motors kinesin and dynein that are
responsible for microtubule-based axonal transport [101]. This suggests that
axonal transport dysfunction can lead to axonal degeneration and that defective
axonal transport may play a role in the etiology of PD.
Mice expressing the PD-associated LRRK2 mutation (R1441G) exhibit
PD-like motor symptoms that respond to L-dopa. These mice do not have SN DA
neuron loss but exhibit fragmented DA axons that have axonal spheroids and
form dystrophic neurites [102]. Meanwhile, the G2019S and I2020T LRRK2
mutations exhibit dramatic reductions in neurite length and branching yet only
slight changes in cell soma diameter in primary neuronal cultures [35]. Similar
findings were made for the G2019S mutant in differentiated neuroblastoma cells
[103] and in primary neurons derived from transgenic mice [104]. In addition,
Parkin protects DA neurons against colchicine, a known microtubuledepolymerizing agent [105]. Lastly, PINK1 may also play a role in axonal
trafficking and hence the health of the axonal compartment via its association
with Miro and Milton, two proteins that are involved in axonal mitochondrial
transport [106]. Taken together, these data support the notion that there are
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persistent early changes in axonal health and trafficking in PD, changes that may
contribute to PD pathogenesis.
1.4.4 Toxin studies
A similar pattern of neurodegeneration is also evident in toxin models of
PD. For example, severe terminal field loss yet relatively mild nigral changes are
also observed in response to MPTP treatment in primates [107-108]. This
specific terminal field effect is consistent with data showing that this toxin can
destabilize microtubules in cell-free assays, affect tubulin levels in differentiated
PC12 cells [109-110], and impede the clearance of -synuclein by impairing
dynein activity [111]. More directly, MPP+ affects axonal transport in the squid
giant axon by increasing retrograde transport and decreasing anterograde
transport independent of the cell’s ATP production [112]. In the mammalian PC12
cell line MPP+ also affects axonal mitochondrial trafficking by destabilizing
microtubules [113]. Thus, toxin models of PD also support the idea that axonal
transport dysfunction, and subsequent axonal degeneration, is important in the
progression of PD.
Rodent models lesioned with 6-OHDA also lead to depletion of striatal
nerve terminals followed by retrograde degeneration of neurons in the SN [71].
Like MPP+, 6-OHDA also destabilizes microtubules in in vitro cell-free assays
suggesting that microtubule destabilization is a common pathway to axon
degeneration [114]. Consistent with this notion, rotenone, another well known PD
mimetic, was reported to induce DA neuron death through microtubule
depolymerization [115]. In addition, rotenone impairs mitochondrial transport in
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differentiated SH-SY5Y cells, a neuroblastoma cell line that exhibits a DA
phenotype [116]. Finally, intrastriatal injection of colchicines blocks retrograde
axonal transport and subsequently causes degeneration of the striatonigral
pathway [117]. Therefore, changes in axonal structure or transport can potentially
mediate the “dying back” mechanism observed in PD.
Taken together, there is a growing body of data from post mortem studies,
genetic and toxin models indicating that axon dysfunction plays a key role in PD.

1.4.5 Programmed cell death versus axonal degeneration
It was initially thought that axons were highly dependent on cell bodies for
long-term survival. However, recent studies reveal the existence of axonautonomous mechanism(s) that regulate rapid axon degeneration after injury
[118]. For example, axons of sympathetic neurons die back after localized NGF
withdrawal, while the cell body survives [119]. In contrast, local application of
NGF to the axonal terminal promotes survival of both the axon and cell body
[120]. More directly, caspase-3, which is involved in programmed cell death, is
not activated in a variety of axonal degeneration models [121]. In the context of
PD, Ries et al. examined how c-jun N-terminal kinases (JNKs), which play a
central role in mitogen-activated protein kinase (MAPK)-mediated apoptosis of
SN DA neurons, affect 6-OHDA-mediated degeneration of DA axons. They found
that homologous JNK2/JNK3 null mice show almost complete protection of their
SN cell bodies but no protection of axons against 6-OHDA [122]. Further
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evidence that axons can survive even in the presence of cell body death is seen
from

Wallerian

degeneration-slow

(WldS)

mice.

This

mutation

arose

spontaneously from C57/Bl/6 mice and has been demonstrated to cause delayed
Wallerian degeneration in the peripheral nerve after axotomy [123]. Studies show
that the cell bodies of sympathetic neurons from WldS mice degenerate with a
normal timecourse and morphology but that WldS neurites remain metabolically
active in response to injury [124]. These studies suggest that the degeneration of
neurites and cell bodies occur through mutually exclusive processes, and that the
protection of one compartment does not necessarily lead to protection of the
other.

1.5

Wallerian degeneration-slow (WldS) mice
Wallerian degeneration is similar to the “dying back” phenomenon in that

the distal stump of an injured axon degenerates first. This occurs in four phases:
1) the distal stump loses the ability to transmit action potentials; 2) the axon and
synaptic terminals fragment; 3) the cytoskeleton degenerates; and 4) Schwann
cells and invading macrophages remove axonal and nerve terminal debris [125].
As their names suggests, WldS mice exhibit delayed degeneration of neurites
following

axotomy

or vincristine treatment but does not delay neuronal cell

death following such insults [123]. This phenomenon is also observed in other
axon disease models. For example, in the mouse model for progressive motor
neuron (pmn) disease, crossing WldS mice with pmn mice protects neurites but
not cell bodies against degeneration [126]. In contrast,, crossing pmn mice with
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mice overexpressing Bcl-2, an anti-apoptotic protein, protects motorneuron cell
bodies but not axonal degeneration [127]. These results suggest that Wallerian
degeneration appears to occur through a different mechanism than apoptosis.
WldS mice also protect axons in other disease models such as myelinrelated

axonopathy

[128],

gracile

axonal

dystrophy

[129],

autoimmune

encephalomyelitis [130], ischemia [131], Alzheimer’s disease [132], and the toxin
models of PD [62, 133]. In terms of the latter, Sajadi et al. have shown that unlike
wild type mice, WldS preserves nigrostriatal projections but not SN cell bodies
following 6-OHDA administration [133]. Similarly, Hasbani and O’Malley
observed an even more pronounced preservation of terminal fields after MPTP
treatment in WldS versus wild type animals [62]. Taken together, these data
suggest that understanding the mechanisms underlying WldS axon protection
may aid in the development of potential therapies for many neurodegenerative
diseases, including PD.
The WldS gene encodes an in-frame fusion protein of the amino (N)terminal 70 (N70) amino acids of ubiquination factor E4B (Ube4b), which is linked
by a unique 18-amino acid region to the complete coding region of the
nicotinamide adenine dinucleotide (NAD+) synthesizing enzyme, nicotinamide
adenylytransferase 1 (Nmnat1) [134] (Figure 1). The fusion protein is localized to
the nucleus due to the nuclear localization signal present on the Nmnat1 portion
of the protein [135]. Coleman and colleagues have shown that transgenic
animals expressing this fusion protein recapitulate the WldS phenotype [136]. At
present, the components of the WldS sequence that are required for axon
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protection and which downstream factors are involved in this process remains
controversial. Several mechanistic hypotheses have been proposed.

1.5.1 Ube4b
Because inhibiting UPS delays axonal degeneration [136], the Ube4b part
of the WldS fusion protein may be responsible for its neuroprotective effect.
However, the WldS fusion gene contains only the first 70 amino acids of Ube4b,
not the 123 amino acid sequence essential for its ubiquination activity. Hence,
gain of multi-ubiquitination function is unlikely as the WldS protein lacks the U-box
motif. Dominant-negative inhibition of Ube4b is another possibility since
expression of the yeast deubiquitinating enzyme UBP2 delays axonal
degeneration in olfactory receptor neurons [137]. However, Ufd2, the yeast
homologue of Ube4b, is a positive survival factor [138] and inhibition of UPS is
linked to neurodegeneration rather than neuroprotection [139]. UPS has also
been shown to be required for both developmental neuronal pruning and injuryinduced axon degeneration, while WldS has no effect on neuronal pruning [137].
Moreover, overexpression of Ube4b does not protect differentiated Neuro2A cells
against vincristine [140] or dorsal root ganglion cells (DRGs) against axotomy
[141].
Although Ube4b activity may not be critical to WldS actions, the deletion of
16 amino acids (N16) of the Ube4b portion of WldS completely suppresses the
axon protection afforded by WldS in mice [142] and greatly weakens the
protection of axons in Drosophila [143]. Mechanistically, the N16 portion of the
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fusion protein co-immunoprecipitates with valosin containing protein (VCP/p97)
[144]. VCP is a AAA-ATPase with key roles in UPS and membrane fusion [145].
Consequently, although WldS lacks Ube4b’s ligase activity, it maintains its ability
to bind VCP which may target the fusion protein to areas critical for its activity.

1.5.2 Nmnat1
In contrast to Ube4b, in certain experimental paradigms the Nmnat1
portion of WldS is sufficient for axon protection in vitro, acting either through the
silent information regulator (SIRT1) [146] or through local NAD+ synthesis in
neurites [147]. Consistent with Nmnat1’s NAD+ synthesizing capabilities,
exogenous application of NAD+ can protect DRGs against degeneration [141].
Not all studies have shown the same results, however, even in the same model
system [148]. In support of a model requiring the complete WldS fusion protein,
transgenic mice that only overexpress Nmnat1 show normal rates of Wallerian
degeneration [148]. However, cytoplasmically [149] or axonally targeted Nmnat1
transgenic animals [150] are equally if not more effective at protecting at least
peripheral model systems than WldS. Thus, cell type specific effects must exist
with needing the complete WldS fusion gene to protect some axons but have
Nmnat1 to be sufficient in other cases.
Disparity in results hold true in Drosophila, as well since Avery et al. [151],
showed that Nmnat’s enzymatic activity is required to protect axons following
axotomy whereas Zhai et al., [152] found that Nmnat does not need its catalytic
domain to protect axons. The latter study [152], as well as a new study
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demonstrating that Nmnat also protects dendrites [153], both indicate that Nmnat
exhibits a separate chaperone-like activity which protects axons and dendrites
[152, 154]. These studies support the role of Nmnat in protecting against
degeneration, but not though its traditional role in NAD+ synthesis.
Two other isoforms of Nmnat exist, Nmnat2 and Nmnat3. Nmnat2 is highly
expressed in the brain compared to Nmnat1 and 3 and is primarily localized in
the Golgi complex [155]. Overexpression of Nmnat2 protects DRG and superior
cervical ganglia (SCG) axons following axotomy [156] [157]. In either case,
protection is dependent upon Nmnat2’s NAD+ synthesizing activity [156,157].
Similar results are true for Nmnat3, a mitochondrially localized isoform of Nmnat
[158]. Nmnat3 is thought to promote axonal protection by mitigating the effects of
ROS [159]. Based on these studies, it appears that the site of action plays a role
in Nmnat’s effectiveness in protecting against axonal degeneration [160].
Despite the data in Drosophila, in peripheral vertebrate model systems it
appears that the NAD+ enzymatic activity of WldS is required since mutating key
amino acids abolishes the neuroprotection [135-136]. Collectively, these studies
suggest that the fusion protein has acquired a gain of function not normally
present in the neuron and that the entire fusion gene is necessary for protection.

1.5.3 Axonal structure and function
Other studies have attempted to determine how the WldS protein protects
through a more localized analysis of its effects on the axon. Suzuki et al. found
that microtubule acetylation, a post-translational modification associated with
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microtubule stability, is enhanced in cultured cerebellar granule cells in WldS mice
[161]. In other studies, activation of SIRT2, a NAD+-dependent tubulin
deacetylase, abolishes WldS resistance to axonal degeneration by colchicine
[162]. Specific to PD, inhibition of SIRT2 using small interfering RNA rescued
cells from -synuclein mediated toxicity [163]. These data suggest that the
neuroprotective effect of WldS may be mediated by its effect on microtubule
stabilization.
Consistent with a role in stabilizing microtubule tracks, a microarray study
using WldS mice crossed with pmn mice reported that 56 genes were
differentially expressed between pmn and pmn x WldS mice [164]. None of the
canonical “apoptosis” genes were altered, rather a large proportion of the genes
that were upregulated were related to retrograde and anterograde transport (e.g.
dynactin and kinesin) [164]. These studies suggest that WldS protects axons by
maintaining proper axonal transport after injury.

1.5.4 Mitochondrial function
Mitochondrial dysfunction appears to be an early event in the
degeneration of neurites [165]. For example, treatment of SCG neurons with the
microtubule-disrupting agent, vinblastine, decreases m and induces neurite
degeneration. In contrast, WldS mice maintain their m and have intact neurites
leading to the proposal that preservation of m may mediate the axonal
protection seen with WldS [166]. Recently, Barrientos et al. reported that WldS is
able to regulate the mitochondrial permeability transition pore and prevent
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calcium release, ATP loss, oxidative stress and release of proteins involved in
axonal degeneration [167]. Although WldS is primarily in the nucleus, it appears
to associate with mitochondria, albeit in lower levels than seen in the nucleus
[162]. In addition, differential proteomics analysis comparing WT and WldS
striatal synaptosomes identified 16 protein that were differentially expressed, 8 of
which are mitochondrially-associated proteins [132]. Finally, Shen et al. has
shown that WldS preserves mitochondrial trafficking in isolated cortical axons
during chemical ischemia [168]. Taken together, WldS may protect axons by
preserving or enhancing mitochondrial function.
Collectively, the current body of literature suggest that WldS may protect
axons by (1) preventing a decline in energy, (2) preventing degradation of axonal
structure, (3) preventing the impairment of key motor proteins involved in axonal
transport, and/or (4) by priming mitochondria to have a more robust response to
degeneration-inducing stimuli.

Fig 1.1 - Mouse WldS fusion protein structure (GenBank accession number
AAG17285). Amino acid residue numbers relative to Ube4b and Nmnat1 are
shown. From Fainzilber (2006) [3].
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1.6

Goals of the current study
Observations from work done by our lab [62] and others [5, 169] have

suggested that, in PD, DA neurons degenerate through a “dying back”
axonopathy wherein degeneration begins in the distal axon and progresses over
time towards the cell body. Therefore, processes that delay axonal degeneration
might slow PD progression. Previous work in our lab has demonstrated that WldS
mice protect DA terminal fields in the striatum from MPTP injury [62]. At present,
the mechanisms underlying WldS-mediated axonal protection are unclear. Some
studies have attributed WldS neuroprotection to the Nmnat1 portion of the protein
while others have observed upregulation in genes involved in axonal structure
and transport in WldS mice compared to controls. More recently, WldS’ action on
the mitochondria has been suggested to be important component of its
neuroprotective effect. It is unknown at this time which, if any, of these
mechanisms underlies WldS protection of DA axons. Consequently, the overall
goals of this work are to 1) test the hypothesis that the entire WldS fusion protein
is required for axonal protection from parkinsonian mimetics in DA neurons, and
2) to test the hypothesis that WldS protects DA axons by directly affecting axonal
mitochondria such that they are not impaired following toxin treatment.
With these goals in mind, we discuss which portion of the WldS gene
protects DA neurites from MPP+ and 6-OHDA toxicity in Chapters 2 and 3,
respectively. In addition, we test the neuroprotective effects of other isoforms of
Nmnat in DA neurons as well as whether exogenous addition of NAD+ and NAD+
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precursors are sufficient to protect DA neurons against MPP+ and 6-OHDA in a
similar manner to WldS neurons.
To study the effects of WldS specifically on DA axonal structure and
function, we describe a novel system to segregate DA axons from the cell bodies
in Chapter 4. Using this unique compartmented chamber, we test the hypothesis
that impaired axonal transport plays a role in MPP+-induced axonal degeneration.
Finally, we evaluate whether WldS is able to prevent the changes in mitochondrial
motility and velocity observed in wild type DA axons after MPP+ treatment in
Chapter 5.
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Abstract
The WldS mouse mutant (“Wallerian degeneration-slow”) delays axonal
degeneration in a variety of disorders including in vivo models of Parkinson’s
disease. The mechanisms underlying WldS-mediated axonal protection are
unclear, although many studies have attributed WldS neuroprotection to the
NAD+-synthesizing Nmnat1 portion of the fusion protein. Here, we used
dissociated dopaminergic (DA) cultures to test the hypothesis that catalytically
active Nmnat1 protects DA neurons from toxin-mediated axonal injury. Using
mutant mice and lentiviral transduction of DA neurons, the present findings
demonstrate that WldS but not Nmnat1, Nmnat3, or cytoplasmically-targeted
Nmnat1 protects DA axons from the parkinsonian mimetic N-methyl-4phenylpyridinium (MPP+). Moreover, NAD+ synthesis is not required since
enzymatically-inactive WldS still protects. In addition, NAD+ by itself is axonally
protective and together with WldS is additive in the MPP+ model. Our data
suggest that NAD+ and WldS act through separate and possibly parallel
mechanisms to protect DA axons. As MPP+ is thought to impair mitochondrial
function, these results suggest that WldS might be involved in preserving
mitochondrial health or maintaining cellular metabolism.
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2.1

Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative

disorder in the U.S., affecting 1-2% of people over the age of 55. Characterized
by loss of dopaminergic neurons in the substantia nigra (SN) [1-2], the cardinal
motor symptoms of PD include resting tremor, bradykinesia, rigidity, and
abnormal gait [3-4]. Another characteristic of PD is its late onset and progressive
nature. Symptoms appear after 50-70% [5-6] of striatal dopamine (DA) has been
depleted and 30-50% [7-8] of the nigral DA cells have died. Such studies suggest
that the extent of striatal DA depletion is better correlated with the severity of PD
symptoms than the loss of DA neurons in the SN [7].
Data from PD-linked genetic mutations also support the notion that axonal
pathology and/or dysfunction occurs prior to the loss of DA cell bodies. For
example, -synuclein pathology is seen in neurites before it is observed in PDassociated cell bodies [3, 9]. α-synuclein mutants accumulate in the cell soma
when overexpressed in cortical neurons, suggesting impaired axonal transport as
well [10]. Moreover, transgenic models expressing the PD-linked mutant gene
leucine rich repeat kinase 2 (LRRK2) also exhibit pronounced axonal loss and
pathology prior to cell body loss [11]. In addition, genetic mutations in other PDlinked genes such as Parkin, an E3 ligase [12], and PINK1 (PTEN-induced
putative kinase 1 protein) a mitochondrially-targeted kinase, also alter axonal
transport [13-14]. Collectively, these findings have led to the idea that nigral
neurons degenerate through a “dying back” axonopathy where degeneration
starts in the distal axon and proceeds over time towards the cell body.
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Environmental toxins known to mimic PD such as rotenone and MPP + also
disrupt axonal function. These factors not only inhibit mitochondrial Complex I
activity, but also de-polymerize microtubules leading to axon fragmentation and
decreased synaptic function [15-17]. Moreover, MPP+ can directly inhibit axon
transport in the squid axoplasm [18] and DA neurons [19]. Thus, results from PDassociated environmental and genetic factors support an early, critical role for
axonal impairment in PD.
Recent data suggest that the Wallerian degeneration slow fusion protein
(WldS) can delay axonal degeneration about 10-fold from a wide variety of
genetic and toxin-inducing stimuli in the peripheral nervous system [20]. WldS
also blocks axon degeneration in several central nervous system (CNS) models
of degeneration including animal models of PD [21-22]. For example, we
previously found that WldS rescues 85% of DA axons for at least 7 days post
MPTP treatment in vivo [23]. Because no other mutation or drug protects axons
as robustly as WldS, understanding how the WldS fusion protein is able to prevent
axon degeneration is the first step towards defining an intervention that would
leave axons intact.
WldS is a chimeric protein composed of the first 70 amino acids of the
ubiquitination factor E4b (Ube4b) followed by an 18-amino acid linker region and
then

the

entire

coding

sequence

for

nicotinamide

mononucleotide

adenylyltransferase (Nmnat1), a nicotinamide adenine dinucleotide (NAD+)
synthesizing enzyme [20]. Most studies suggest that catalytically active Nmnat1
is necessary for axonal protection [24-25], hence, exogenous addition of NAD+
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has been reported to delay Wallerian degeneration in response to axotomy in
dorsal root ganglion (DRG) cells [26]. In Drosophila, however, the picture is more
complex in that Avery et al. [27] showed that Nmnat enzymatic activity is required
following axotomy whereas Zhai et al. [28] found that Nmnat does not need its
catalytic domain to protect axons. In this model [28], as well as in a new study
demonstrating that Nmnat also protects dendrites [29], Nmnat exhibits a separate
chaperone-like activity which protects axons and dendrites [28, 30].
Inasmuch as most studies have been done in peripheral model systems
and because we have previously shown that WldS protects DA terminal fields
from MPTP in vivo, we used a dissociated midbrain culture system to determine
the mechanism of WldS-mediated neurite protection in DA neurons. Here, we
show that, regardless of its enzymatic activity, the entire WldS sequence is
needed for the WldS’ neuroprotective phenotype in DA neurons. Our data also
illustrate that NAD+ has a neuroprotective effect that is different from WldSmediated protection.

2.2

Materials and methods

2.2.1 Cell culture and toxin treatment
For primary midbrain cultures, the ventral mesencephalon was removed
from embryonic day 14 (E14) murine embryos as previously described [31-32].
Wild-type (C57/Bl6) and WldS (C57Bl/OlaHsd-WldS) mice were ordered from
Harlan (Bichester, UK). SIRT1 knockout mice were obtained from Dr. Christian
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Sheline (Louisiana State University – Health Science Center, New Orleans, LA).
Cytoplasmic WldS (Cyto WldS) mice were obtained from Dr. Michael Coleman
(Babraham Institute, UK). Animals were treated in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals. All
procedures were approved by the Washington University School of Medicine
animal experimentation committee. Plates were pre-coated overnight with 0.2
mg/ml poly-D-lysine (Sigma-Aldrich, St. Louis, MO). Cells were plated at a
density of approximately 125,000 cells/cm2 and maintained in serum-free
Neurobasal medium (Invitrogen, Carlsbad, CA) supplemented with 1X B27
supplement (Invitrogen), 0.5 mM L-glutamine (Sigma-Aldrich), and 0.01 µg/ml
streptomycin plus 100 U penicillin. Half of the culture medium was replaced with
fresh Neurobasal medium after 5 days in vitro (DIV). Cultures were pretreated
with 1 mM NAD+, 1 mM NMN, 1 mM nicotinic acid mononucleotide (NaMN), or a
comparable volume of vehicle 24 hours before toxin treatment. Cultures were
treated with either 1 M 1-methyl-4-phenylpyridinium (MPP+), the active
metabolite of MPTP or vehicle on DIV 7. Dorsal root ganglion (DRG) cells were
obtained from E14 murine embryos as previously described [33]. Cells were
plated on coverslips precoated with 0.1 mg/ml poly-L-ornithine (Invitrogen) and
32 µg/ml laminin-1 (Invitrogen) and maintained in DRG media which consisted of
Eagle Minimal Essential Media (Invitrogen) supplemented with chick embryo
extract (Invitrogen), 10% fetal calf serum (Invitrogen), 50 ng/ml Nerve Growth
Factor (Harlan Biosciences, Madison, WI) and 50 U/ml penicillin–50 g/ml
streptomycin. Half of the culture medium was replaced with fresh DRG medium
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after DIV 5. After transduction with lentivirus on DIV 2, DRG cultures were
treated with 0.4 M vincristine or vehicle on DIV 7. NAD+, NMN, NaMN, MPP+,
and vincristine were all obtained from Sigma-Aldrich.

2.2.2 Lentiviral infection of DA neurons
The lentiviral expression plasmids FUGW, FCIV-WldS, FCIV-Nmnat1,
FCIV-Ube4b, FCIV-Nmnat3, FCIV- Nmnat1(W170A), FCIV-cytNmnat1, and
FCIV-WldS(W258A) were obtained from Dr. Jeff Milbrandt (Washington
University, Saint Louis). Lentiviruses expressing transgenes were generated by
the Hope Center for Neurological Disorders Viral Core (Washington University,
Saint Louis). For infection of DRG and primary midbrain neurons, 50 l lentivirus
(105 infectious units/l) was added to the well of a 7-mm dish containing
approximately 70,000 neurons on DIV 2. Transduced primary midbrain and DRG
neurons were treated with MPP+ and vincristine, respectively, on DIV 7. Viral
infection and transgene expression was monitored using the GFP reporter via
fluorescent microscopy.

2.2.3 Immunocytochemistry
Primary DA cultures and DRGs were plated in 7 mm microwell plates
(MatTek Corp., Ashland, MA). Cells treated with MPP+ were fixed with 4%
paraformaldehyde (PFA) in PBS after 48 hours. Cultures were stained with
sheep polyclonal anti-tyrosine hydroxylase (TH) (Novus Biologicals, Littleton,
CO) and Cy3 anti-sheep antibodies (Molecular Probes, Carlsbad, CA).
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Localization of cytoplasmic WldS was confirmed using rabbit WldS (gift of M.P.
Coleman) and Alexa488 anti-rabbit antibodies (Molecular Probes). TH+ cells and
neurites

were

counted

using

unbiased

stereological

methods

(Stereo

Investigator, MicroBrightField, Williston, VT). DRG cultures treated with
vincristine were subsequently stained with mouse acetylated tubulin (SigmaAldrich) and Cy3 α-mouse antibodies (Molecular Probes). Neurites were counted
as described above. All images were acquired by confocal microscopy (Olympus
Fluoview 500, Olympus, Center Valley, PA) and processed in ImageJ (NIH).

2.2.4 Western Blotting
Primary midbrain cultures were plated in 48-well plates and transduced
with the transgene of interest as described above. Lysates were collected in
RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% NaDoc, 0.1% SDS, 50 mM
Tris pH 8.0) with protease inhibitor mixture (Roche, Mannheim, Germany) and
incubated on ice for 30 minutes.

Insoluble cell debris was removed by

centrifugation and the protein concentration of each cell lysate was determined
by Bradford protein assay (BioRad, Hercules, CA). Equal amounts of protein
were run on SDS-polyacrylamide gels and transferred to polyvinylidene diflouride
(PVDF) membranes (BioRad). PVDF membranes were probed with either rabbit
WldS antibody or chicken polyclonal anti-GFP antibody (Aves Labs, Tigard, OR).
As a control, PVDF membranes were also probed with goat polyclonal antiHRP60 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The secondary
antibodies used were either a HRP-linked rabbit antibody or HRP-linked anti-
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chicken

antibody

and

a

HRP-linked

anti-goat

antibody

(Jackson

Immunoresearch, West Grove, PA). Membranes were developed with enhanced
chemiluminescence

(Amersham

Biosciences),

imaged

with

a

Storm

PhosphorImager (Molecular Dynamics) and band intensities were determined
using ImageQuant software (Amersham Biosciences).

2.2.5 Statistical analysis
GraphPad Prism software (San Diego, CA) was used for statistical
analysis. All data was collected from a minimum of three independent
experiments done in triplicate. The significance of effects between control and
experimental conditions was determined by a Student t-test or one-way ANOVA
with Bonferroni Multiple Comparisons tests.

2.3

Results

2.3.1 WldS protects DA cell bodies and neurites from MPP+
Previously we have shown that DA terminal fields but not cell bodies of
WldS mice are protected against MPTP injury [23]. To confirm and extend these
observations in a more tractable system, we utilized dissociated cultures of
midbrain neurons in which 1-5% of the total cells plated are DA [31]. Results
show that cultures from WldS mice exhibited significant protection of neurites not
seen in wild type (WT) cultures after MPP+ treatment (Fig. 2.1A,C). Moreover, DA
cell death from MPP+ treatment was also attenuated in WldS cultures, unlike
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those seen in vivo (Fig. 2.1A,B). Thus WldS can effectively protect neurites
(dendrites and axons) as well as cell bodies from known PD mimetics in vitro.

2.3.2 Cytoplasmic WldS protects cell bodies and neurites against MPP+
Recent studies have reported that the localization of WldS influences its
neuroprotective effect. Beirowski et al. have reported that a cytoplasmic version
of the WldS protein confers a higher level of protection than the native form of
WldS [34]. In addition, Milbrandt and colleagues have reported that cytoplasmic
Nmnat1 and Nmnat3, which is primarily localized in the mitochondria, also confer
a higher level of protection than Nmnat1 [35-36]. To test whether cytoplasmic
localization of WldS rescued or changed the level of protection seen with nuclear
WldS, primary DA neurons were prepared from WT and cyto WldS mice, treated
with MPP+, and analyzed as described. Results show that cyto WldS mice
exhibited a similar level of protection of DA cell bodies and neurites as seen in
WldS mice (Fig 2.2). Therefore, as reported for peripheral model systems, WldS
does not have to be localized in the nucleus; it can also protect neurites from the
cytoplasm.

2.3.3 Nmnat1 does not protect against MPP+ toxicity
Many studies, especially in peripheral model systems, have shown that
Nmnat1 can at least partially mimic the effects of WldS [24, 37]. To determine
whether this is true in DA neurons, we transduced primary midbrain cultures from
WT animals with either GFP, WldS, the 70 amino acid fragment of Ube4b found
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in WldS, or the entire coding region of Nmnat1 using lentiviral vectors expressing
GFP [37] (Fig. 2.3). We also tested the effects of Nmnat3, cytoplasmic Nmnat1
(cyto Nmnat1), and enzymatically inactive Nmnat1 (Nmnat1 (W170A)) [25-26]
(Fig 2.3A). Western blotting was done to confirm that transductions led to similar
expression levels in dissociated cultures (Fig. 2.3B-D). Despite equivalent levels
of transgene expression, only neurites transduced with the entire coding
sequence of WldS were protected from MPP+ injury (Fig. 2.3F).
Because many studies have suggested that Nmnat and in particular cyto
Nmnat or axonally targeted Nmnat can be as effective as WldS in protecting
axons from mechanical or toxic insults, we used DRG cultures as a positive
control [38-39]. Consistent with those studies, both WldS and cyto Nmnat rescued
DRG neurites from the neurotoxin, vincristine, whereas the GFP-only and
inactive WldS virus did not (Fig 2.4). Taken together, these data confirm previous
results showing that cyto Nmnat is necessary and sufficient to save DRG
neurites. In contrast, only WldS but not cyto Nmnat, Nmnat1, or Nmnat3 was able
to protect DA neurons from the neurotoxic effects of MPP+.

2.3.4 Inactive WldS protects cell bodies and neurites against MPP+
To corroborate the hypothesis that Nmnat1 does not protect DA neurons
from MPP+, we transduced dissociated primary midbrain cultures with
enzymatically inactive WldS (W258A; [37]). In contrast to our own results in DRG
cultures (Fig. 2.4) as well as results published by others using this same
construct [37], the inactive WldS plasmid was as effective as NAD+-synthesizing
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WldS animals in protecting DA cell bodies and neurites against MPP+ injury (Fig.
2.5). Therefore, the entire WldS chimeric protein, but not its NAD+-synthesizing
activity, is required for neuroprotection of DA neurons.

2.3.5 NAD+ protects cell bodies and neurites against MPP+
Previous studies have shown that NAD+ itself can be neuroprotective [37].
Although Nmnat1 by itself did not recapitulate the neuroprotective effect of WldS
on dopaminergic neurons, we tested whether NAD+ or one of its precursors (Fig.
2.6A) rescued cell bodies or neurites from MPP+ treatment. Therefore,
dissociated DA WT cultures were pretreated with either 1 mM of NAD+,
nicotinamide mononucleotide (NMN), or nicotinic acid mononucleotide (NaMN)
24 hours before MPP+ treatment. Both NAD+ and NMN but not NaMN protected
cell bodies and neurites against MPP+ toxicity (Fig. 2.6B,C). These findings
together with the results showing that catalytically-inactive WldS was able to
protect DA neurons (Fig. 2.5) but catalytically active Nmnat did not (Fig. 2.3F)
suggest that different pathways are being invoked in response to MPP + toxicity.

2.3.6 SIRT1 is not responsible for the NAD+-mediated protection of cell
bodies and neurites against MPP+
Previous studies in DRG neurons have attributed the protective phenotype
of WldS to its action on the Nmnat1-NAD+-SIRT1 pathway [37]. To test the
involvement of SIRT1, we prepared dissociated DA cultures from SIRT1
knockout mice. Following 24 hour pretreatment with 1 mM NAD+ or vehicle
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control, cultures were exposed to MPP+. Consistent with the notion that NAD+ is
not acting through SIRT1 but rather through a different mechanism, NAD+
protected cell bodies and neurites in SIRT1 knockout cultures from MPP+ toxicity
(Fig. 2.7).

2.3.7 NAD+ and WldS effects are additive
The data described above suggest that WldS is acting through a separate
possibly parallel pathway from that of NAD+ in DA neurons. If so, then adding
NAD+ to WldS cultures will enhance the neuroprotective phenotype of WldS. To
see whether the NAD+ effect overlapped with WldS or was additive, dissociated
DA cultures were prepared from WT and WldS mice and pretreated with and
without NAD+ as previously described. Both NAD+ and WldS alone exhibited
similar levels of cell body and neurite protection (Fig. 2.8). However, NAD +
together with WldS generated significantly higher levels of protection suggesting
this is an additive process (Fig. 2.8). To test whether these effects were maximal,
additional cultures were treated with 5 mM NAD+; no significant differences in
neuroprotection were observed when compared with the lower dose of 1 mM
NAD+ (Fig. 2.8D). These findings demonstrate that NAD+ and WldS are additive in
the MPP+ model suggesting that they are acting through separate and possibly
parallel neuroprotective mechanisms.
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2.4

Discussion
The mechanism(s) by which WldS protects axons is still unclear.

Peripheral model studies underscore the role of Nmnat and its product, NAD +, in
protecting axons from various injuries whereas few central nervous system
studies have been done. Using cellular, molecular and pharmacological tools,
the present findings show that the chimeric WldS gene product plays a critical
role in protecting DA processes, one not dependent upon Nmnat activity.
Specifically, neither Nmnat, cytoplasmically-targeted Nmnat, nor Nmnat 3 were
able to prevent toxicity associated with the DA toxin, MPP+ whereas, akin to
previous reports [26, 37], cyto Nmnat protected DRG axons from known axonal
toxins. In contrast, WldS, cytoplasmically-expressed WldS, and WldS with an
inactive Nmnat domain, all significantly protected DA neurites from toxinmediated loss. Despite the inability of Nmnat to protect DA processes, NAD+ and
its precursor, Nmn, were neuroprotective. As WldS and NAD+ were additive in
this model system, current results suggest that these protectants act through
separate, possibly parallel pathways. Thus, NAD+ or its derivatives as well as
WldS and its targets protect DA processes and may aid in the development of
therapeutics preserving the connections and circuitry important in PD.
The role of Nmnat and NAD+ in recapitulating the full effect of WldS has
been controversial. In vitro studies have shown that overexpression of Nmnat1
by itself protects axons from many mechanical, genetic or toxin-induced injuries
[20, 40]. In contrast, transgenic animals expressing nuclear Nmnat1 did not
replicate the effects of WldS [41-42] whereas cytoplasmically [38] or axonally
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targeted Nmnat1 [39] were equally if not more effective. Thus, site of action plays
a role in Nmnat1’s effectiveness [20]. These data together with findings showing
that the first 16 N-terminal amino acids of the WldS gene product are required for
full WldS protection [24], possibly by redistributing enough WldS to cytoplasmic or
axonal compartments, are consistent with the notion that both the N-terminal
portion of WldS and Nmnat1 are necessary for full axonal protection [20].
The importance of Nmnat catalytic activity is reflected in several
mutational studies in which Nmnat’s active sites have been disrupted and
neuroprotection was lost [24, 27, 37, 42]. Moreover, NAD+ itself and/or some of
its biosynthetic precursors, protect against axonal degeneration in peripheral
model systems as well as in experimental autoimmune encephalomyelitis (EAE;
[26, 43], ischemia [44-45], Alzheimer’s disease [46], and PD [47-49]. In at least
one study however, addition of NAD+ was not effective [41]. Moreover,
Drosophila Nmnat (dNmnat) did not require enzymatic activity for axon protection
against insults such as excitotoxicity, polyglutamine-induced dysfunction, or
mechanical injury [30] leading to the suggestion that dNmnat may perform a
chaperone-like function [28]. Indeed, structural studies of various Nmnats have
revealed characteristic similarities to known chaperones such as UspA and
Hsp100 [50]. Consistent with this notion, dNmnat was recently shown to function
as a stress protein in response to heat shock, hypoxia, and the mitochondrial
Complex I toxin, paraquat [51]. However, in DA neurons, Nmnat1 does not seem
to function as either an axonal protectant or a chaperone.
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Studies have indicated that MPP+ can block electron transport by acting at
the same site as the Complex I inhibitor, rotenone, leading to the production of
free radical species and a loss of ATP production [52-54]. MPP+ affects other
processes as well including the rapid release of DA from vesicular stores [55-56];
depolymerization of microtubules [16, 57]; induction of autophagy [19, 58], and
the rapid loss of mitochondrial membrane potential and reduction in
mitochondrial motility in DA axons [19] . Since many of these effects involve
mitochondrial function, conceivably the WldS gene product is involved in
preserving mitochondrial health or maintaining homeostatic control. Recently,
Barrientos et al. reported that WldS is able to regulate the mitochondrial
permeability transition pore (PTP) preventing, amongst other things, calcium
release, ATP loss, oxidative stress and release of proteins involved in axonal
degeneration [59]. This is consistent with other studies from Wishart et al.
showing that striatal synaptosomes isolated from WldS versus WT animals
expressed higher levels of various mitochondrial proteins including the PTP
protein, VDAC2 [60]. Barrientos et al. suggested that WldS is part of a regulatory
cascade that also involves JNK activation upstream of PTP opening [59].
Although JNK is a known regulator of axon degeneration [61], recently we
showed that the JNK inhibitor, SP600125, did not prevent MPP+ effects on DA
mitochondria [19]. Thus diverse, unknown, regulatory steps appear to mediate
WldS effects in DA axons.
Given its role as a ubiquitous cofactor, NAD+ influences many cellular
decisions such as DNA damage repair [62] and transcriptional regulation and
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differentiation [63]. Earlier studies suggested that increased NAD+ levels led to
SIRT activation which, in turn, activated a transcription factor that induced genes
involved in neuroprotection [30, 37]. Although an attractive hypothesis,
subsequent studies using SIRT1 knock out animals did not support this notion for
DRG neurons [64], or as in the present study, for DA neurons (Fig 2.8).
Why are results in DA neurons different than other systems? Because
many of the studies published have been performed in peripheral model systems
with dramatically over-expressed protein, there may be neuronal-specific or
expression level-related effects that might account for the differences. For
example, WldS has shown protection in several central nervous system models,
but few have been further tested with only Nmnat1 even in dissociated neuronal
models. Then too, DA axons may have intrinsic differences that contribute to the
WldS effect. For instance, DA neurons have fewer [65], smaller and slower
mitochondria than non-DA neurons [19]. Moreover, DA neurons produce a
neurotransmitter prone to oxidation [66], exhibit a greater dependence on L-type
Ca2+ channels with subunits that result in deleterious amounts of intracellular
calcium and ensuing mitochondrial dysfunction [67], and extend long, thin lightlymyelinated processes which are selectively vulnerable in PD [68]. These unique
characteristics in DA neurons may require higher levels and/or different forms of
a neuroprotective agent in order to be effective.
In support of our previous in vivo study showing that WldS protects DA
terminal fields from MPTP [23], the current results demonstrate in dissociated DA
cultures that the entire WldS sequence is needed for axonal protection,
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regardless of its NAD+-synthesizing activity. Indeed, NAD+ and WldS act through
separate, possibly parallel, mechanisms to protect DA axons. As MPP+ is thought
to impair mitochondrial function, these results suggest that WldS might be
involved in preserving mitochondrial health or maintaining cellular metabolism.
Given that Parkinson’s disease is the second most common neurodegenerative
disease, our findings support the idea that studies expanding therapeutic efforts
towards maintaining connections as well as saving the cell body will help in
developing better interventions for PD.
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Figure 2.1 - Wlds protects DA neurons from MPP+ toxicity. (A) Dissociated
DA cultures from both WT and Wlds mice were treated with 2 m MPP+ for 48
hours, and processed for TH immunoreactivity. (B) Quantification of TH+ cell
bodies and (C) TH+ neurites was done using unbiased stereology. Data are
normalized to control cultures and denote the mean ± SEM of representative
determinations made in three separate cultures. *p<0.01; **p<0.001.
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Figure 2.2 - Cytoplasmic Wlds protects DA neurons from MPP+ toxicity. (A)
Dissociated DA cultures from both WT and cyto Wlds mice were co-stained with
TH and Wlds antibodies to confirm the subcellular localization of Wlds. (B)
Cultures were treated with 2 m MPP+ for 48 hours prior to fixing and staining.
(C) Quantification of TH+ cell bodies and (D) TH+ neurites shows that
cytoplasmic WldS protected both cell bodies and neurites against MPP +. Data are
normalized to control cultures and denote the mean ± SEM of representative
determinations made in three separate cultures. *p<0.05.
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Figure 2.3 - Nmnat by itself does not protect DA neurons from MPP+
toxicity. (A) Diagram of the lentiviral constructs used to transduce WT
dissociated DA neurons. (B-D) Quantification of the western blots illustrates that
all the transduced transgenes exhibit similar levels of expression. (E)
Quantification of TH+ cell bodies and (F) TH+ neurites show that only WldStransduced cultures protected neurites against MPP+. Data are normalized to
control cultures and denote the mean ± SEM of representative determinations
made in three separate cultures. *p<0.001.
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Figure 2.4 - Wlds and cytoplasmic Nmnat1 protect DRG axons from
vincristine toxicity. (A) DRG cultures from E14 mice transduced with GFP,
Wlds, cyto Nmnat1, or inactive Wlds were processed for acetylated tubulin
immunoreactivity 24 hours after vincristine treatment. (B) Quantification of
neurites shows that both Wlds and cyto Nmnat1 protects DRG neurites from
vincristine toxicity. Data are normalized to control cultures and denote the mean
± SEM of representative determinations made in three separate cultures.
*p<0.05.
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Figure 2.5 - Inactive Wlds also protects DA neurons from MPP+ toxicity. (A)
Dissociated DA neurons transduced with GFP or inactive Wlds were treated and
processed as described. (B) Quantification of TH+ cell bodies and (C) TH+
neurites. Data are normalized to control cultures and denote the mean ± SEM of
representative determinations made in three separate cultures. *p<0.05.
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Figure 2.6 - NAD+ protects DA cells and neurites from MPP+ toxicity. (A)
NAD+ biosynthetic pathway [69]. (B) Dissociated WT DA cultures were pretreated
with NAD+, NMN, or NaMN 24 hours before addition of 2 m MPP+.
Quantification of TH+ cell bodies and (C) TH+ neurites show that NAD+ and
NMN, but not NaMN, protected cells and neurites from MPP+. Data are
normalized to control cultures and denote the mean ± SEM of representative
determinations made in three separate cultures. *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.7 - NAD+ does not protect DA neurons through the Sirt1 pathway.
(A) Dissociated midbrain cultures from both WT and Sirt1 KO mice were
pretreated with NAD+ 24 hours before addition of 2 m MPP+. (B) Quantification
of TH+ cell bodies and (C) TH+ neurites show that NAD+ protects cells and
neurites from MPP+ in both WT and Sirt1 KO cultures. Data are normalized to
control cultures and denote the mean ± SEM of representative determinations
made in three separate cultures. *p<0.05.
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Figure 2.8 - The protective effect of NAD+ and WldS are additive. (A)
Dissociated midbrain cultures from both WT and WldS mice were pretreated with
NAD+ 24 hours before addition of 2 m MPP+. (B) Quantification of TH+ cell
bodies and (C) TH+ neurites show that NAD+ pretreatment was more effective in
protecting WldS neurites from MPP+ versus untreated WldS cultures. (D) NAD+
dose response curve showing that the protection seen with 1 mM NAD + is
maximal. Addition of 10 mM NAD+ before MPP+ treatment induced 50% cell
death in DA neurons (data not shown). Data are normalized to control cultures
and denote the mean ± SEM of representative determinations made in three
separate cultures. *p<0.05; **p<0.001.
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Chapter 3

S

Wld but not Nmnat1 protects dopaminergic neurites from 6-OHDA
neurotoxicity

This manuscript is in preparation for publication
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Abstract:
The WldS mouse mutant (“Wallerian degeneration-slow”) delays axonal
degeneration in a variety of disorders including in vivo models of Parkinson’s
disease. The mechanisms underlying WldS-mediated axonal protection are
unclear, although many studies have attributed WldS neuroprotection to the
NAD+-synthesizing Nmnat1 portion of the fusion protein. We used dissociated
dopaminergic (DA) cultures to test the hypothesis that catalytically active Nmnat1
protects DA neurons from the parkinsonian mimetic 6-hydroxydopamine-(6OHDA). Using mutant mice and transduced DA neurons, the present study
demonstrates that the entire WldS protein, but not Nmnat1 or cytoplasmicallytargeted Nmnat1, protects DA axons from 6-OHDA. Additionally, exogenous
NAD+ was not able to protect DA axons against 6-OHDA. Our data suggest that
WldS protects DA axons against 6-OHDA independent of its NAD+-synthesizing
ability. Therefore, WldS may induce a novel gain of function that counteracts the
effects of 6-OHDA such as the generation of reactive oxygen species and/or
mitochondrial dysfunction.
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3.1

Introduction
Parkinson’s

disease

(PD)

is

a

late

onset

and

progressive

neurodegenerative disorder that affects 1-2% of people over the age of 55 in the
United States. PD is caused by the death of DA neurons in the substantia nigra
(SN) [1-2] and characterized by the occurrence of resting tremor, bradykinesia,
rigidity, and abnormal gait in patients [3-4]. Interestingly, symptoms of PD
manifest after 50-70% [5-6] of striatal dopamine (DA) has been depleted and 3050% [7-8] of the nigral DA cells have died. These data are consistent with the
hypothesis that PD severity correlates better with the extent of striatal DA
depletion than with the loss of DA neurons in the SN [7].
PD-linked genetic mutations provide further evidence that axonal
degeneration occurs prior to DA cell body loss. For example, -synuclein
inclusions have been reported to be present in neurites prior to the appearance
of inclusions in neuronal cell bodies [3, 9]. Transgenic models expressing the
PD-linked mutant gene leucine rich repeat kinase 2 (LRRK2) also exhibit
decreased DA terminal fields and increased dystrophic processes with abnormal
axonal swellings [10]. In addition, overexpression of PD-linked LRRK2 mutations
lead to dramatic reductions in neurite length and branching yet only slight
changes in cell soma diameter in primary neuronal cultures [11].
Environmental toxins known to induce Parkinson-like symptoms in animals
such

as

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

(MPTP)

and

6-

hydroxydopamine (6-OHDA) also exhibit terminal field changes prior to cell body
loss. For example, MPTP administration in primates leads to marked reductions
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of DA axons prior to the loss of nigral cell bodies [12]. In mice, Serra and
colleagues showed that one day after MPTP treatment, striatal DA levels were
diminished by 60% whereas at this same time point no tyrosine hydroxylase (TH)
immunoreactive cell bodies were lost in the SN [13]. Other studies using 6-OHDA
showed that striatal DA levels in the 6-OHDA-lesioned side of rodents were
decreased by 64% whereas DA was reduced by only 43% in the lesioned SN.
[14]. Similarly, Ebert et al. demonstrated that four days after 6-OHDA treatment,
TH levels were significantly reduced in the striatum whereas there was very little
loss of TH staining in the SN [15]. Finally, studies by Rosenblad et al. showed
that even one day after 6-OHDA injection, axons already exhibited damaged
pathology and retraction from the striatum whereas cell death was only observed
weeks after toxin treatment [16-18].
Taken together, studies from PD patients as well as evidence from both
genetic and toxin models of PD support the idea that nigral neurons degenerate
through a “dying back” axonopathy in which degeneration begins in the distal
axon and proceeds over weeks or months towards the cell body [19-20]. Hence,
interventions that can halt or delay the progression of axonal degeneration may
play an important role in designing therapeutics for PD.
Mice with the Wallerian degeneration slow (WldS) mutation exhibit
dramatically delayed axonal degeneration in response to a wide range of genetic
and toxin-inducing stimuli in both peripheral nervous system (PNS) [21] and
central nervous system (CNS) models of degeneration [22-25]. In fact, WldS
provides axon protection in a model of anterograde degeneration induced by
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injection of 6-OHDA into the medial forebrain bundle [23, 25]. Because no other
mutation or drug protects axons as robustly as WldS, understanding the
mechanism by which the WldS fusion protein is able to prevent axon
degeneration is the first step towards developing an intervention that would leave
axons intact.
WldS is a chimeric protein composed of the first 70 amino acids of the
ubiquitination factor E4b (Ube4b) followed by an 18-amino acid linker region and
the entire coding sequence for nicotinamide mononucleotide adenylyltransferase
(Nmnat1), a nicotinamide adenine dinucleotide (NAD+) synthesizing enzyme (Fig.
3.1A) [21, 26]. Most studies have attributed the neuroprotective effect of WldS to
the Nmnat1 portion of the protein, since enzymatically inactive WldS or Nmnat1
does not recapitulate the neuroprotection seen with the native WldS protein in
certain model systems [27-28]. In support of these studies, exogenous addition
of NAD+ delays Wallerian degeneration in response to axotomy in dorsal root
ganglion (DRG) cells [29]. In Drosophila, however, there is evidence both for [36]
and against [30] the role of Nmnat’s enzymatic activity for neuroprotection. In the
latter model [30], as well as in a new study demonstrating that Nmnat also
protects dendrites [31], neuroprotection of axons and dendrites by Nmnat has
been attributed to a separate chaperone-like activity [30, 32].
Because it has previously been reported that WldS protects DA terminal
fields from 6-OHDA in vivo [23], we used a dissociated midbrain culture system
to determine if Nmnat1 is responsible for the WldS-mediated neurite protection in
DA neurons. We found that the entire WldS sequence is needed for the WldS’
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neuroprotective phenotype against 6-OHDA in DA neurons and present data
showing that NAD+ cannot protect against 6-OHDA-mediated toxicity.

3.2

Materials and methods:

All of the methods and materials for these set of experiments were
performed exactly as described for Chapter 2 with the exception that cultures
were treated with 20 M 6-OHDA with ascorbic acid dissolved in N2-bubbled
water instead of MPP+ on DIV 7.

3.3

Results

3.3.1 WldS protects DA cell bodies and neurites from 6-OHDA
DA terminal fields but not cell bodies are protected against 6-OHDA
treatment in WldS mice [23]. To validate these observations in a more
manipulable system, we utilized dissociated cultures of midbrain neurons in
which 1-5% of the total cells plated are DA cells [33]. Cultures from WldS mice
but not control animals exhibited significant protection of neurites after 6-OHDA
treatment (Fig. 3.2A,C). In contrast to in vivo results [23], DA cell bodies were
also protected from 6-OHDA treatment in WldS versus control cultures (Fig.
3.2A,B), demonstrating that WldS effectively protects neurites (dendrites and
axons) as well as cell bodies from a known PD mimetic in vitro.
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3.3.2 Nmnat1 does not protect DA neurons against 6-OHDA toxicity
Many studies done in PNS model systems have shown that Nmnat1
completely or partially mimics the effects of the entire fusion protein [28, 34]. To
determine whether this is true in DA neurons, we transduced primary midbrain
cultures from wild type (WT) animals with either GFP, the entire WldS coding
region, the 70 amino acid fragment of Ube4b encoded within the WldS gene,
Nmnat1, or cytoplasmically-targeted Nmnat1 (cyto Nmnat1) using lentiviral
vectors expressing GFP [34] (Fig. 3.2). Western blotting was done to confirm that
transductions led to similar expression levels in dissociated cultures (Fig 2.3).
Despite equivalent levels of transgene expression, only cell bodies and neurites
transduced with the entire coding sequence of WldS were protected from 6OHDA injury (Fig. 3.2B,C). In addition, although cyto Nmnat1 protects
dissociated DRG cultures from vincristine treatment in our studies (Fig 2.4) and
in others [35], it was unable to protect DA neurons from 6-OHDA. These data
confirm and extend the hypothesis that WldS has a cell type-specific effect in
given neuronal populations.

3.3.3 NAD+ does not protect DA cell bodies and neurites against 6-OHDA
It has been previously reported that exogenous application of NAD+ on
DRGs is neuroprotective [34]. Although transduced Nmnat1 did not rescue DA
neurons from 6-OHDA treatment (Fig. 3.2), inadequate levels of viral
transduction may have affected the outcome. Conversely, NAD+ might act in a
parallel fashion. Consequently, we tested whether exogenous addition of NAD+
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or one of its precursors (Fig. 3.3) could rescue cell bodies or neurites from 6OHDA treatment. Dissociated primary midbrain WT cultures were pretreated with
either 1 mM NAD+, nicotinamide mononucleotide (NMN), or nicotinic acid
mononucleotide (NaMN) 24 hours before addition of the toxin. None of these
pretreatments protected against 6-OHDA toxicity (Fig. 3.3) suggesting that the
NAD+-synthesizing activity of WldS is not necessary for its neuroprotective effect
against 6-OHDA toxicity.

3.4

Discussion
To date, no consistent hypothesis has emerged on the mechanism(s)

underlying

WldS-mediated

axonal protection.

PNS

model

studies

have

emphasized the role of Nmnat in protecting axons from various injuries whereas
few CNS studies have confirmed this role. Using cellular, molecular and
pharmacological tools, our study shows that the WldS protein plays a critical role
in protecting DA processes, but not through its NAD+-synthesizing activity.
Specifically, Nmnat1, cyto Nmnat1 and NAD+ are all able to protect peripheral
model systems from toxicity [35,43] whereas none were able to do so in 6OHDA-treated dissociated DA cultures. These data support the notion that WldS
acts in a cell specific manner to rescue neurites from degeneration.
The importance of Nmnat’s NAD+ synthesizing ability is underscored in
several studies in which Nmnat’s active sites were disrupted and neuroprotection
was subsequently lost [28, 34, 36-37]. Moreover, NAD+ itself and/or some of its
biosynthetic precursors, protect against axonal degeneration in different disease
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model systems such as autoimmune encephalomyelitis [29, 38], ischemia [3940], Alzheimer’s disease [41], and PD [42-44]. In at least one study, addition of
NAD+ was not effective [45]. In addition, a study in Drosophila found that Nmnat’s
enzyme activity is not necessary for axon protection following mechanical injury,
excitotoxic or polyglutamine-induced dysfunction [32], suggesting that dNmnat
may perform a chaperone-like function [30]. In fact, structural studies of the three
different Nmnat isoforms have revealed characteristic similarities to known
chaperones such as UspA and Hsp100 [46]. Consistent with this notion, dNmnat
was recently shown to function as a stress protein in response to heat shock,
hypoxia, and paraquat [47]. However, Nmnat1 does not seem to function as
either an axonal protectant or a chaperone in DA neurons.
Our lab has shown that 6-OHDA-oxidized proteins cause ER stress and
upregulation of the unfolded protein response (UPR), which regulates protein
folding, protein degradation and protein translation leading to cell death of
dopaminergic neurons [48]. Activation of UPR-associated proteins such as IRE1α
was seen in axotomized motoneurons [49], implying a relationship between the
UPR and axonal degeneration. More recently, Bernstein et al. has found that 6OHDA-generated ROS induces DNA damage and causes cell death through a
p53-dependent mechanism. Cultures from p53 knockout mice exhibited
protection of both their cell bodies and neurites against 6-OHDA injury [50]. Thus,
6-OHDA may also cause axonal degeneration through its effect on p53. Finally,
6-OHDA causes rapid mitochondrial depolarization in both human neuroblastoma
cell lines (SH-SY5Y) [51-52] and DA neurons [33] demonstrating a direct effect
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on mitochondrial function. Since mitochondrial dysfunction can trigger axonal
degeneration [53], loss of neurites following 6-OHDA treatment might be entirely
due to direct changes in membrane potential.
Given the possible means by which 6-OHDA can cause axonal
degeneration, WldS potentially preserves axons against 6-OHDA injury through
different mechanisms. For instance, WldS may protect against 6-OHDA toxicity
by working as an antioxidant. Mouse embryonic fibroblasts from WldS mice show
protection against paraquat, a PD-linked toxin known to generate ROS [54].
Therefore, similar to the case of paraquat, WldS can function as an antioxidant
that protects DA axons against 6-OHDA-mediated neurite degeneration. As
described before, Nmnat may also have chaperone activity based on studies in
Drosophila and on structural similarities to identified chaperone proteins. Even
though we found that Nmnat1 by itself could not protect DA axons against 6OHDA, it is still possible that WldS itself has chaperone activity and that the 70
amino acid N-terminal fragment of WldS imparts some necessary function in the
preservation of DA neurons. Although Nmnat1 has been linked to SIRT1
activation, an NAD+-dependent histone deacetylase, which is in turn linked to p53
regulation [55], the fact that neither Nmnat nor NAD+ rescued DA neurons from
6-OHDA toxicity would make this a less likely regulatory pathway.
In regards to 6-OHDA’s effect on the mitochondria, a recent study has
found that WldS is able to regulate the mitochondrial permeability transition pore
(mPTP) [53], therefore affecting mitochondrial health. This is consistent with
other studies showing that striatal synaptosomes isolated from WldS versus WT
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animals expressed higher levels of various mitochondrial proteins including the
mPTP associated protein, VDAC2 [56]. Therefore, the WldS protein may also
protect against 6-OHDA-mediated injury by preserving mitochondrial integrity.
Additional studies are underway to explore these possibilities.
In vivo, WldS provided remarkable axon protection in a model of
anterograde degeneration induced by injection of 6-OHDA into the medial
forebrain bundle. But surprisingly, WldS did not confer protection against a
retrograde model of DA axon degeneration by injection of 6-OHDA into the
striatum [23]. These findings were confirmed by Cheng et al. in transgenic mice
that express green fluorescent protein using the TH promoter to visualize and
quantify DA axons following injury [25]. These results identify a definitive,
fundamental difference between mechanisms of anterograde and retrograde
degeneration in DA axons. It will be interesting to see whether these findings are
recapitulated in vitro using our microchamber devices (Chapter 4).
In support of previous in vivo work showing that WldS protects DA terminal
fields from 6-OHDA, our study demonstrates that the entire WldS sequence is
needed for axonal protection against 6-OHDA-mediated toxicity in dissociated
DA cultures. We also show that NAD+ by itself is not able to confer protection of
DA neurons against 6-OHDA. This suggests that the WldS protein may produce a
novel gain of function that counteracts the effects of 6-OHDA such as the
generation of ROS, activation of UPR, p53 upregulation, and/or mitochondrial
dysfunction. Given that PD is the second most common neurodegenerative
disorder, our findings support the idea that studies expanding therapeutic efforts
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towards maintaining connections as well as saving the cell body will help in
developing better interventions for PD.
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Figure 3.1 - Wlds protects DA neurons from 6-OHDA toxicity. (A) Schematic
of mouse WldS fusion protein structure. GenBank accession number AAG17285,
adapted from Coleman (2005). Amino acid residue numbers relative to Ube4b
and NMNAT1 are shown [57]. (B) Dissociated DA cultures from both WT and
Wlds mice were treated with 20 m 6-OHDA for 24 hours, and processed for TH
immunoreactivity. (C) Quantification of TH+ cell bodies and (D) TH+ neurites was
done using unbiased stereology. Data are normalized to control cultures and
denote the mean ± SEM of representative determinations made in three separate
cultures. *p<0.01; **p<0.001.
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Figure 3.2 - Nmnat1 by itself does not protect DA neurons from 6-OHDA
toxicity. (A) Dissociated DA cultures from WT mice were transduced with
transgenes for GFP, WldS, 70AA-Ube4b, Nmnat1, and cyto Nmnat1 at DIV2 then
treated at DIV7 with 20 m 6-OHDA for 24 hours, and processed for TH
immunoreactivity. (B) Quantification of TH+ cell bodies and (C) TH+ neurites
show that only WldS-transduced cultures protected cells and neurites against 6OHDA. Data are normalized to control cultures and denote the mean ± SEM of
representative determinations made in three separate cultures. *p<0.001.
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Figure 3.3 - NAD+ does not protect DA cells and neurites from 6-OHDA
toxicity. (A) Dissociated WT DA cultures were pretreated with NAD+, Nmn, or
Namn 24 hours before addition of 20 m 6-OHDA. (B) Quantification of TH+ cell
bodies and (C) TH+ neurites show that none of the pretreatments protected cells
and neurites from 6-OHDA. Data are normalized to control cultures and denote
the mean ± SEM of representative determinations made in three separate
cultures.
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The Parkinsonian Mimetic, MPP+, Specifically Impairs Mitochondrial
Transport in Dopamine Axons
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Abstract
Impaired axonal transport may play a key role in Parkinson’s disease. To
test this notion, a microchamber system was adapted to segregate axons from
cell bodies using green fluorescent protein-labeled mouse dopamine (DA)
neurons. Transport was examined in axons challenged with the DA neurotoxin,
1-methyl-4-phenylpyridinium

ion

(MPP+).

MPP+

rapidly

reduced

overall

mitochondrial motility in DA axons; among motile mitochondria, anterograde
transport was slower yet retrograde transport was increased. Transport effects
were specific for DA mitochondria, which were smaller and transported more
slowly than their non-DA counterparts. MPP+ did not affect synaptophysin-tagged
vesicles or any other measureable moving particle. Toxin effects on DA
mitochondria were not dependent upon ATP, calcium, free radical species, JNK,
or caspase3/PKC pathways but were completely blocked by the thiol-anti-oxidant
N-acetyl-cysteine or membrane-permeable glutathione. Since these drugs also
rescued processes from degeneration, these findings emphasize the need to
develop therapeutics aimed at axons as well as cell bodies to preserve “normal”
circuitry and function as long as possible.
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4.1

Introduction
Impaired axonal transport plays an important role in a variety of

neurodegenerative disorders, including Parkinson disease (PD) [1]. Postmortem
studies on PD patients show widespread axonal pathology that appears to
precede the loss of cell bodies [2], supporting the notion that nigral neurons
degenerate through a “dying back” axonopathy [3]. Animal models of PD-linked
genes also point to axonal impairment as being a critical factor. For example,
transgenic mice expressing the PD-linked R1441G LRRK2 mutation exhibit
decreased dopamine (DA) terminal fields together with increased dystrophic
processes and abnormal axonal swellings, findings consistent with DA
axonopathy [4]. Reduced axonal transport is also seen with -synuclein mutants,
which accumulate in the cell soma when overexpressed in cortical neurons [5].
Moreover, vesicle-associated -synuclein binds to microtubule motor proteins
like kinesin and dynein, underscoring a potential role in microtubule-dependent
axonal transport [6]. In addition, genetic mutations in Parkin, an E3 ligase, and
PINK1, a mitochondrially targeted kinase, lead to impaired mitochondrial
dynamics, resulting in altered transport and distribution of mitochondria as well
as loss of synaptic function [7]. PINK1 can also form a complex with Miro and
Milton [8], proteins known to recruit kinesin to the mitochondria and promote
motility along microtubule tracks [9]. Thus, these PD-linked mutations are
consistent with the idea that axonal dysfunction plays an early and significant role
in the disorder. Environmental toxins mimicking PD such as N-methyl-4-phenyl1,2,3,6-tetrahydropyridine

(MPTP)

or
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its

active

derivative,

1-methyl-4-

phenylpyridinium ion (MPP+), also disrupt axonal function. MPTP-treated
monkeys [10] or mice [11] first lose DA terminal fields and then exhibit cell body
loss. Moreover, Wallerian degeneration slow (WldS) mutant mice rescue DA
projections in MPTP-treated animals but not cell bodies, emphasizing the
independence of cell body function versus axon specialization [12]. In addition,
MPP+ can directly inhibit axon transport in the squid axoplasm [13]. Although the
mechanisms underlying the latter response are unclear, in vertebrate models
MPP+ depolymerizes microtubules, leading to axon fragmentation and decreased
synaptic function [14-15]. Difficulty in assessing real-time changes in DA axons
has precluded testing models of structural or trafficking impairment. Although
much can be learned from the squid giant axon, this system as well as studies in
vertebrate peripheral, cortical, or other non-DA cell types [15], may be
unrepresentative of a bona fide DA neuron. Recently, we have adapted a
microchamber system in which axons are segregated to one side, leaving cell
bodies and dendrites on the other. When used with GFP-labeled DA neurons
derived from genetically engineered mice, DA axons can be examined using
targeted fluorescent markers and time lapse imaging. Using these chambers,
here we show that MPP+ specifically decreases mitochondrial movement in DA
axons. We also explore potential mechanisms underlying the effect of MPP+ on
mitochondrial transport in DA axons.
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4.2

Materials and Methods

4.2.1 Cell culture and microchamber devices
Murine mesencephalic cultures were prepared, treated with toxin for
indicated time periods, then fixed and stained for tyrosine hydroxylase (TH) as
described previously [16]. TH-positive cell bodies and neurites were counted
using Stereo Investigator (MBF Bioscience). DA/GFP cultures were prepared
from embryonic day 14 Tg(TH-EGFP)DJ76GSAT transgenic mice (Gene
Expression Nervous System Atlas, National Institutes of Health, Bethesda, MD).
Typically DA/GFP males were mated with wild-type females. Brains isolated from
the resulting embryos were screened for GFP fluorescence before midbrain
dissection. GFP-positive tissue was pooled and plated. Microchamber devices
were modified from Ivins et al. [17]. Briefly, 20mmglass bottom culture dishes
(MatTek) were coated with 100 g/ml Matrigel (BD Bioscience), rinsed with
DMEM/F-12, and dried. A polytetrafluoroethylene Teflon tubing [17 (outside
diameter) x 13 (inside diameter) x 2 (wall thickness) x 5 mm (length)] was cut in
half and attached to the bottom of the dish using sterile vacuum grease. A
rectangular glass coverslip (9 x 18 mm) was sandwiched between both pieces of
Teflon and sealed in place with a Matrigel/collagen complex (1 mg/ml collagen
type I, 3 mg/ml Matrigel, DMEM). Isolated neurons (250,000 cells/cm 2) were
plated on one side of the chamber in DMEM/F-12, 5% FBS, supplemented with
B-27

(Invitrogen)

and

penicillin/

streptomycin.

Axonal

chambers

were

supplemented with 300 g/ml NetrinI (R&D Systems) to direct axonal outgrowth

103

under the coverslip. Transport was assessed between days in vitro (DIV) 12 and
14.

4.2.2 Determination of cell viability
To determine DA cell viability following MPP+ treatment both in cell bodies
and neurites, mesencephalic cultures were processed for TH immunoreactivity
and counted using Stereo Investigator (MBF Bioscience). Briefly, 50 fields were
assayed per dish leading to the quantification of 200–300 TH neurons and 2000–
5000 neurites/dish. Experiments were repeated 3–5 times using cultures isolated
from independent dissections.

4.2.3 Quantification of tubulin
The tubulin-mCherry construct was prepared by replacing the EGFP
sequence of pEGFP-tubulin (Invitrogen) with mCherry (Dr. Mike Nonet,
Washington University, St. Louis, MO). Neurons were transfected using
Lipofectamine 2000 (Invitrogen) at DIV5-6 and imaged 1 d later. Live images
were taken at 1, 3, 6, and 24 h after MPP+ treatment. Tubulin integrity was also
measured by immunostaining with antibodies against tyrosine hydroxylase (PelFreez Biologicals) and acetylated tubulin (AcTub; Sigma) on the axonal side of
microchamber devices. TH-positive axons with at least three AcTub breaks per
40 m of axon were considered damaged and calculated as the percentage total
of all TH-positive axons.
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4.2.4 Autophagy
Cells were transfected with a GFP-tagged LC3 expression vector (kindly
provided by Dr. Chris Weihl, Washington University) at DIV5-6 as previously
reported(Kumaet al., 2007). A day later, cells were treated with 2 M MPP+ for
the indicated time, fixed, and immunostained with a rabbit anti-TH antibody (PelFreez

Biologicals).

Cy3-conjugated

secondary

antibodies

(Jackson

ImmunoResearch Laboratories) were used for visualization. TH-positive neurons
with LC3-GFP granules were counted using Stereo Investigator (MBF
Bioscience).

4.2.5 Optical imaging
At DIV12–14, mitochondria on the axonal chamber side were labeled with
25 nM MitoTracker Red (MTR; Invitrogen). Plasmids containing mitochondrially
targeted Dendra2 and synaptophysin fused in frame with cerulean (Syn-Cer)
were provided by Evrogen and Dr. Rachel Wong (University of Washington,
Seattle, WA), respectively. Subsequently, mitochondrially targeted Dendra2 and
Syn-Cer were inserted into the FUGW lentiviral expression vector provided by Dr.
Jeffrey Milbrandt (Washington University). Lentiviral preparations were generated
using HEK 293T cells as described previously (Araki et al., 2004). DA/GFP
cultures were inoculated with virus at DIV2 for 4–6 h and imaged at DIV12–13.
Images were taken using a Zeiss LSM510 Meta NLO Multiphoton System (Carl
Zeiss) on Axiovert 200M inverted microscope with 40x water objective [CApochromat 40x/1.2W Corr.1.2 numerical aperture, collar correction (0.14–0.18)]
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equipped with a 5% CO2/37°C controlled chamber. Filter sets used for
visualizing a given fluorescent marker included 488 nm argon laser and 505 long
pass emission filter (GFP and Dendra2), 543 nm HeNe laser and 560 long pass
emission filter [MTR, tetramethylrhodamine ethyl ester (TMRE), or tubulinmCherry], and 458 nm argon laser and 466–514 meta emission filter (Syn-Cer).
Sixty images at 5 sec intervals were acquired before addition of toxin and then
again 30 min after 2 M MPP+ treatment.

4.2.6 Image analysis
Kymographs were created using ImageJ/Multiple Kymograph (NIH,
Bethesda, MD). In all cases, direction was determined by identifying the axonal
terminal from tile scanned images. To calculate particle speed in each direction,
the following approach was adopted. Diagonal lines were drawn for each moving
particle on a kymograph. Angle and length information were collected for each
particle’s diagonal line. Distance and time were calculated using the following
equations in which 112.5 m was the frame length, 512 the pixel size, and 5 sec
the interval of time-lapse images:

Distance (m) = (112.5 * {Length * COS[RADIANS(Angle)]})/ 512

(1)

Time (s) = 5 * {-Length * SIN[RADIANS(Angle)]}

(2)

Total numbers of particles were obtained using particle analysis with a threshold
image. Only particles moving a minimum of 5 m in length for at least 15 sec
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within the imaging time were counted. Particle size was assessed using
ImageJ/Particle analysis. Anterograde movements are expressed as positive
integers whereas retrograde movement is expressed by negative integers.

4.2.7 [3H]Dopamine release
DA release on the microchamber devices was measured as described
previously [18](Lotharius and O’Malley, 2000). Briefly, cells were loaded in both
somal and axonal sides with 2.4 Ci/ml [3H]DA/Krebs–Ringer solution for 20 min
at 37°C and washed 3 times for 3 min. Radioactive counts from a wash sample
were measured using a Beckman scintillation counter and used as a control for
basal levels of [3H]DA release. Cells were then treated with MPP+ for 10 min, and
the amount of [3H]DA released during this time period was counted. Cultures
were then washed extensively and maintained in [ 3H]DA-free Krebs–Ringer
solution. Following medium collection, cells were lysed in 0.1 N perchloric acid by
freeze thawing, and residual, intracellular [3H]DA was measured. Total counts
and percentages were calculated.

4.2.8 Mitochondrial membrane potential and size
Cells were loaded with either 50 nM TMRE (Invitrogen) or MTR for 15 min
and medium was subsequently added for a final concentration of 25 nM.
Mitochondrial potential was assessed based on changes in TMRE fluorescence
before and after toxin treatment as described by Ward [19]. The cross area of
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axonal mitochondria was estimated by MTR fluorescence using ImageJ/ particle
analysis.

4.2.9 Statistical analysis
One-way ANOVA and unpaired two-tailed Student’s t test were used for
statistical analysis (SAS, GraphPad Software).

4.3

Results

4.3.1 MPP+ causes neuritic degeneration and autophagy before cell body
loss
Because MPP+ serves as a substrate for the plasma membrane DA
transporter [20], its toxic effects are highly selective for DA neurons versus the
non-DA interneurons that predominate dissociated mesencephalic cultures.
Consistent with in vivo results showing that loss of DA terminal fields occurs
earlier and is more pronounced than cell body loss [10-11], MPP+ leads to a
significant loss of neurites in dissociated DA cultures before cell bodies are
affected. As early as 12 hours post-MPP+ treatment, neurite loss was apparent
(Fig. 4.1A). It should be noted that most of the “neurites” measured here have
morphological features of proximal dendrites in that they exhibit a wide diameter
that tapers away from the cell body. When compartmentalized axons (Fig.
4.2A,B) were assessed for fragmentation at 12 hours, significantly more
fragmentation was observed (70.3 + 8.9% nontreated axon control versus 50.4 +
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8.4% nontreated dendritic control, p 0.05). These data suggest that axons are
more vulnerable than dendrites in the presence of MPP+. In contrast, TH-positive
cell bodies were not significantly reduced until 24 hours later and then by only
~40% (Fig. 4.1B). Because DA uptake sites vary among DA neurons from the
substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) [20]
and that the described dissociated DA cultures would contain neurons from both
populations, some variability among MPP+ effects is to be expected. Thus, a 40%
death level might represent all of the DA SNpc neurons, yet only a small fraction
of DA neurons arising from the VTA.
Since MPP+ is thought to depolymerize microtubules [14](Cappelletti et al.,
2005), we stained DA/GFP cultures with antibodies directed against acetylated tubulin, a marker of stable microtubules, and examined DA axons for the
presence of beading and/or fragmentation. “Beading” was first observed by 6 h
(Fig. 4.1C, arrowheads), although no significant fragmentation was observed at
this time point (Fig. 4.1D). To confirm and extend this result, the integrity of
tubulin was also assessed by introducing a tubulin-mCherry construct into
dissociated DA cultures. The mCherry-positive axons were examined for breaks
in DA (GFP+) and non-DA (GFP-) processes at various time points following
MPP+ treatment. Consistent with MPP+ effects on acetylated -tubulin, significant
axonal disintegration in DA neurons was not seen until 6 hours posttreatment,
which exceeded 80% by 24 hours (Fig. 4.1E,F). Together, these data indicate
that MPP+ affects one important component of axonal structure, namely the
microtubule tracks, 12–18 hours before significant cell body loss is observed.
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MPP+ has been shown to induce autophagy, a catabolic system to
degrade and recycle damaged proteins and/or organelles [21] within 24 hours in
DA neurons [22]. To determine whether the disruption of microtubule tracks
preceded the induction of autophagic markers such as LC3 (microtubuleassociated protein 1, light chain 3; also known as ATG8) [23], we transfected an
LC3-GFP clone into DA cultures and measured the appearance of autophagic
granules. Under normal conditions, LC3-GFP fluorescence exhibits a diffuse
cytoplasmic distribution (Fig. 4.1G). As early as 3 hours after toxin treatment,
LC3 takes on a punctuated appearance as it localizes to the inner membrane of
forming autophagosomes (Fig. 4.1G,H). This observation confirms and
accelerates the timeframe reported by Zhu et al. [22]. Moreover, these results
suggest that even before damaged microtubules are apparent, other toxininduced molecular events induce hallmarks of autophagy.

4.3.2 MPP+ disrupts mitochondrial axonal transport
MPP+ also inhibits complex I, leading to mitochondrial dysfunction [24]. To
analyze mitochondrial movement, size, and membrane potential (m) in DA
processes, we initially used a microfluidic strategy [25]. However, DA neurons
attached poorly and were highly susceptible to shear stress resulting from
plating, media changes, and/or toxin addition. Using a simplified chamber design
[17], we established compartmented cultures such that: (1) axons were
segregated from cell bodies and dendrites; (2) transport direction was easily
discerned, imaged, and quantified; and (3) cell bodies or axons could be
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independently exposed to drugs, toxins, DNA, etc. (Fig. 4.2A). When we used
dissociated cultures from DA/GFP mice, DA axon terminals could be identified
via GFP fluorescence (Fig. 4.2B). Immunostaining with the dendritic marker
MAP2 (microtubule-associated protein 2) or axon-preferring tau verified that
processes that grew under the glass coverslip were axons, not dendrites (Fig.
4.2C). To avoid overlapping fluorescent emissions in analyzing mitochondrial
movement, we considered several approaches. These included: (1) lipid-based
transfections with mitochondrially targeted DsRed2 (mtDsRed2) and/or the
photoactivatable fluorescent protein Dendra2 (mtDendra2); (2) transductions with
the same constructs packaged as lentiviral particles; and (3) mitochondrial dyes
such as MTR and TMRE. In the first scenario, finding fluorescently labeled
mitochondria in DA/GFP axons for live imaging is hampered by the low numbers
of DA neurons typically isolated (2–5% of the total) and low transfection
efficiencies in these cultures (5%). The second scenario, lentiviral transduction of
fluorescent proteins targeted to the mitochondria (mtDsRed2; mtDendra2), was
more efficient and, at least with mtDendra2, provided the option of following
particles after photoconversion. Caveats associated with the third scenario
include the notion that mitochondrial dyes might interfere with mobility [26-27].
Thus we started these studies using a targeted mtDendra2 lentivirus. Although
Dendra normally emits at the same wavelength as GFP before excitation, it is
easy to discern mitochondrially targeted Dendra in DA axons because the latter
typically exhibit a smooth, homogenous pattern of GFP expression distinct from
the tubulovesicular appearance of mtDendra2 (Fig. 4.2D). That these structures
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represent mitochondria can be shown by colocalization with the fluorescent
lipophilic cation TMRE, which rapidly accumulates in mitochondria (Fig. 4.2D).
Unfortunately, in our system mtDendra2 did not photoconvert with the efficiency
or at the wavelength originally claimed [28]; nonetheless, analysis of
nonconverted mtDendra2 particles showed that MPP+ decreased total numbers
of moving mitochondria (Fig. 4.2E,F). Moreover, MPP+ treatment decreased
mitochondrial speeds in the anterograde direction but increased them in the
retrograde direction (Fig. 4.2G).
Despite the usefulness of mtDendra2, the small number of DA neurons
and variability associated with transduction still made acquiring sufficient data in
multiple

experimental

paradigms

logistically

challenging.

In

contrast,

mitochondrial dyes have the benefit of labeling all mitochondria within a chamber,
ensuring adequate numbers for analysis despite potential limitations such as
diffusion of fluorescence, quenching, and interference with bioenergetic states
[26]. At least some of these limitations can be overcome when low
concentrations (50 nM) of MitoTrackers such as MTR are used [26, 29-31]. In our
studies, excellent loading and labeling of mitochondria was achieved using even
lower concentrations of MTR (25 nM). At this concentration, MTR labeled exactly
the same structures that TMRE did (data not shown). More importantly, when an
identical experimental protocol was used to measure MTR-labeled mitochondria,
essentially the same results as those for mtDendra2 were produced (Fig. 4.3). In
either case, we observed that like other neurons [32], >70% of all axonal
mitochondria were stationary [32]. Of those mitochondria that were moving, over
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50% had stopped after only 30 min of MPP+ treatment (Figs. 4.2F, 4.3B).
Moreover, the number of moving mitochondria was reduced in either the
anterograde or retrograde direction (Figs. 4.2G, 4.3C). In agreement with
previously published values [33], motile DA mitochondria moved with an average
speed of 0.32 m/s in the anterograde direction, whereas a slower rate was
observed in the retrograde direction (0.26 m/s) (Figs. 4.2G; 4.3C). Following
MPP+ treatment these rates were reversed: anterograde velocity was reduced
whereas retrograde speed was accelerated (Figs. 4.2G, 4.3C). Thus, MPP+
rapidly affects both the fraction of motile DA mitochondria and the speed at which
they travel. These data suggest that in this cell system and at this concentration
MTR is a reliable measure of mitochondrial mobility. Importantly, using two
different approaches essentially the same results were observed: MPP+ rapidly
reduced overall mitochondrial motility in DA axons; among motile mitochondria,
anterograde transport was slower yet retrograde transport was increased.

4.3.3 MPP+ does not affect vesicular transport
To determine whether MPP+ affects all cargo movement or just that of
mitochondria, DA/GFP cultures in microchamber devices were transduced with a
lentivirus expressing Syn-Cer (Fig. 4.4A,B). As shown by others [34], the
synaptophysin sequence targets small, rapidly moving particles that do not
colocalize with MTR (Fig. 4.4A). Despite inhibiting mitochondrial movement
within 30 min, MPP+ did not affect the number or speed of synaptophysin-tagged
particles moving in either direction (Fig. 4.3B–D). Since numerous studies have
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also shown that MPP+ is taken up into vesicular compartments where it rapidly
(10 min) leads to the displacement of DA [18], which was reproduced in our
microchamber devices (Fig. 4.5), these results emphasize that the presence of a
neurotransmitter is not a requirement for transport. As synaptophysin labels only
synaptic vesicles, we also examined all moving particles using transmitted light
images. After subtracting out mitochondria from MTR-colabeled axons, the
remaining particles showed no significant difference in movement following toxin
treatment (data not shown). These data underscore the specificity of the MPP+
effect on mitochondria versus general axonal cargos and also rule out damaged
microtubules as a contributing factor in decreased mitochondrial motility.

4.3.4 MPP+ rapidly depolarizes axonal mitochondria
MPP+ inhibition of complex I leads to ROS, loss of m, and eventually
loss of ATP [35]. Previously we showed that MPP+-induced ROS changes
occurred within 15 min in DA cell bodies using dihydrorhodamine and
dihydroethidium [16, 36]. Although we could confirm our cell body results, we
could not quantitate ROS changes in DA axons with these reagents (data not
shown). To determine whether m was altered over the same time period that
movement was reduced, segregated DA/GFP axons were labeled with the
sensitive m indicator TMRE before acquiring baseline images. After 30 min of
toxin treatment, m was significantly reduced in DA (79.8 + 7.23% decrease in
TMRE fluorescence) (Fig. 4.6B) but not non-DA axonal mitochondria (< 12.9 +
7.34% TMRE fluorescent decrease) (Fig. 4.6B), highlighting the DA-specific
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nature of the MPP+ effects. Because bioenergetic declines are thought to shift
fusion/fission dynamics toward fission, resulting in smaller mitochondria [37], we
measured mitochondrial size. Although TMRE-labeled mitochondria appeared to
undergo a decrease in size (Fig. 4.6A), this was due to the loss of TMRE
fluorescence since MPP+ treatment did not decrease the size of MTR-labeled
axonal

mitochondria

(Fig.

4.6C).

Thus,

MPP+

rapidly depolarized

DA

mitochondria but did not reduce their size, at least in the time frame tested.
Collectively, these results are consistent with recent work in hippocampal
neurons showing that depolarized mitochondria travel more rapidly in a
retrograde direction [38].

4.3.5 Thiol-based reagents rescue disrupted transport, neurites, and cells
What are the underlying mechanisms associated with MPP+-mediated
alterations in transport? Conceivably, MPP+-compromised mitochondria block
transport due to the ATP dependency of the molecular motors. In the squid
axoplasm preparation, however, MPP+ effects on fast axonal transport were
independent of ATP production. Rather, MPP+ treatment led to axonal activation
of caspase-3, which in turn cleaved PKC into its catalytically active fragment
[13]. Like the squid preparation, increasing ATP levels in bona fide DA axons via
glucose preincubation (ATP levels increased from 3.93 + 0.20 x 10-12 to 4.88
+ 0.11 x 10-12 mole/g of protein, p-value = 0.002) did not rescue MPP+
effects on mitochondrial motility (Table 4.1). One caveat to this finding is that
there are no methodologies to measure ATP levels in situ. Thus, we cannot rule
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out the possibility that regional variations in ATP levels might underlie the loss of
mitochondrial movement. Unlike the invertebrate preparation, neither the PKC
(Go¨6976) nor the caspase inhibitor, Csp3I-II, blocked MPP+ effects in DA axons
(Table 4.1) although both inhibitors significantly blocked 6-OHDA-induced DA cell
death (Go¨6976: 45.94 + 11.48% and Csp3I-II: 50.70 + 11.58% protection). We
also tested whether Ca2+ chelators would affect mitochondrial transport since
Ca2+ plays a role in axonal loss [39] and is also implicated in DA
neurodegeneration [40]. Neither EGTA nor BAPTA-AM prevented MPP+disrupted mitochondrial transport at concentrations showing intracellular Ca2+
changes in axons using Oregon Green (data not shown). Because axonal injury
induces activation of the c-Jun N-terminal kinase (JNK) family in the peripheral
nervous system [41], we examined whether the general JNK inhibitor SP600125
could rescue toxin-blocked mitochondrial motility in segregated DA axons.
SP600125 did not affect mitochondrial trafficking (Table 4.1) nor did it prevent
MPP+-mediated DA cell death at a concentration that was effective for blocking tbutylhydroperoxide induced DA cell death (64.08 + 2.18% protection). Given that
MPP+ generates ROS via inhibition of complex I or via release of vesicular DA
followed by its cytoplasmic oxidation [16, 42], we tested N acetylcysteine (NAC;
precursor of glutathione), Mn(III)tetrakis(4-benzoic acid) porphyrin (MnTBAP, a
superoxide dismutase mimetic), and glutathione monoethyl ester (GSHEE;
membrane-permeable GSH) as axonal protectants. Remarkably, pretreatment
with the redox-sensitive neuroprotectants NAC and GSHEE completely rescued
MPP+-induced changes in numbers of motile mitochondria, whereas the anti-

116

oxidant, MnTBAP was ineffective at a concentration of 100 M (Table 4.1).
Moreover, NAC pretreatment not only rescued mitochondrial motility but also
MPP+-induced neurite and cell body loss (Fig. 4.7). Thus, NAC or similar drugs
can potentially be useful therapeutic tools. Although these differences may
simply reflect extruded axoplasm responses versus an intact axon, they may also
reflect clear differences between vertebrate and invertebrate mitochondrial
trafficking systems and indicate that redox equilibria may play a critical role in at
least the mammalian processes.

4.3.6 DA mitochondria are smaller and slower than non-DA mitochondria
Recent studies show that nigral DA neurons have lower numbers of
mitochondria in their cell bodies and dendrites than non-DA neurons [43]. To
determine whether differences exist in organelle size or movement between DA
and non-DA axons, we measured various critical attributes of axonal
mitochondria and synaptophysin-tagged vesicles (Table 4.2). Consistent with the
in vivo study [43], DA mitochondria are about half the size of non-DA
mitochondria and are transported almost three times slower. Although the density
of mitochondria along the axon is the same, there are fewer moving mitochondria
in DA versus non-DA axons. Mitochondrial membrane potential is the same.
Similarly, the number of moving vesicles per unit length axon is reduced in DA
versus non-DA axons, but their speed is not (Table 4.2). No difference was found
in other general moving particles. Importantly, non DA mitochondria were not
affected by MPP+ in terms of size, mobility, or speed (Table 4.3). Given that
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these data were acquired from the same experiments in which DA axons were
analyzed, they serve as useful internal controls showing that the loss of signal or
change in parameter is not due to bleaching caused by imaging or other nonspecific effects. Together, these data suggest that DA axons may be more
susceptible to dysfunction than non-DA axons due to innate differences in axonal
mitochondrial characteristics.

4.4

Discussion
Mounting evidence suggests that axonal dysfunction precedes the death

of cell bodies in many neurodegenerative disorders, especially PD. The present
study uses cellular, optical, and pharmacological techniques to provide new
insights into the biological changes underlying toxin-mediated DA axonal
impairment. Results demonstrate: (1) that the PD-mimetic MPP+ affects DA
neuritic processes and microtubule tracks 12–18 hours before cell bodies appear
altered, and neuritic autophagic puncta are visible by 3 hours; (2) MPP+ halts
mitochondrial trafficking in DA but not non-DA axons within 30 min, an event
which precedes autophagy and loss of microtubules; (3) remaining motile
mitochondria exhibit decreased anterograde movement but increased retrograde
trafficking; (4) MPP+ effects are specific for mitochondria, as synaptophysin
tagged vesicles and other detectable moving particles continue normal
movements in either direction; (5) decreased mitochondrial trafficking is
accompanied by a loss of m; (6) loss of mitochondrial movement is not
associated with ATP loss but rather redox changes; (7) DA mitochondria are
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smaller and slower than non-DA organelles, suggesting cell type-specific
differences exist for axonal mitochondria.
Although widely used as an animal model of PD, the mechanism by which
MPP+ kills DA neurons remains equivocal. Previously we have shown that MPP+
induces a protein synthesis-dependent yet caspase-independent cell death in DA
neurons that is partially mediated by ROS [16]. In those studies and this one, DA
cell bodies die over a period of 48 hours following toxin treatment, although early
loss of neurites is consistently observed [16] (Fig. 4.1). Increased free radical
species such as mitochondrial superoxide have been proposed as an important
mechanism underlying the neurotoxicity of MPP+ [44]. Previously, however, we
have shown that MPP+-induced ROS are primarily derived from toxin-released
vesicular DA [18] (Fig. 4.5). Since redistributed, cytoplasmic DA is thought to
form a number of oxidized toxic metabolites, including DA quinones [45], it is
perhaps not surprising that MnTBAP, a cell permeable SOD mimetic, did not
show a protective effect. Conceivably, other types of ROS, including hydroxyl
radicals and/or nitric oxide [44, 46-47], might also play a role in MPP+-mediated
neurotoxicity. What role, if any, these factors play in axonal transport awaits
future study.
Recently, Cartelli et al. [15] also reported that MPP+ affects mitochondrial
trafficking in the pheochromocytoma cell line PC12. In this study, however, MPP +
led to microtubule impairment before transport dysfunction. In contrast, the
present findings show that mitochondrial dysfunction (30 min) (Figs. 4.2, 4.3, 4.6)
precedes microtubule fragmentation in DA axons (Fig. 4.1). Although microtubule
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polymerization is a GTP dependent process [48], it is also controlled by ATP
dependent pathways. For example, the energy-sensing AMP activated protein
kinase is required for microtubule stabilization [49]. Conceivably, MPP+-mediated
energy deprivation over the course of 6 h may underlie microtubule
fragmentation (Fig. 4.1).
A direct effect of MPP+ on axonal transport was first seen in the isolated
squid axoplasm [13]. Despite the evolutionary distance between the squid and
mouse, in both cases MPP+ decreased anterograde trafficking while increasing
retrograde movement. However, in the squid axoplasm, MPP+ affected all
organelles and vesicles moving via fast axonal transport, whereas in bona fide
DA neurons, toxin-mediated effects were specific for mitochondria. Although
model preparations such as the squid axoplasm and/or the noradrenergic
peripheral tumor cell line can yield valuable insights, our results underscore the
uniqueness of a midbrain DA neuron. Indeed, the rapidity and specificity of MPP+
actions on DA axons are striking: toxin effects on mitochondria occur hours
before microtubule tracks fall apart and before cell bodies are lost (Fig. 4.1).
Moreover, neither non-DA mitochondria nor any other detectable type of moving
particle is affected by toxin treatment, confirming the integrity of the microtubule
tracks (Table 4.2). Together, these data point to an early and profound toxinmediated block of mitochondrial trafficking those results in mitochondrial
redistribution away from the synapse back to the soma. Conceivably, damaged
mitochondria moving toward the soma could deliver signals from the axon to the
cell body, leading to the initiation of cell death.
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Mitochondria undergo complex yet continual processes of fusion and
fission that are critical for the exchange of organelle contents, repolarization, or
degradation by autophagy [50]. Two PD-linked genes that are ubiquitously
expressed have also been implicated in this process. Current data indicate that
PINK1 is selectively stabilized on depolarized mitochondrial membranes [51].
This in turn acts as a signal for Parkin recruitment, which tags Pink-positive
depolarized mitochondria for destruction via autophagy [51-53]. The latter studies
would predict that following MPP+ treatment and bioenergetic declines, PINK1
will be stabilized and Parkin will then be recruited to the PINK-tagged organelles
before the appearance of autophagic puncta in DA axons. One caveat to this
model, however, is that the previous studies were conducted in cell lines. A
recent report examining PINK1 recruitment of Parkin in bona fide neurons did not
see depolarization-mediated Parkin recruitment or autophagy [54]. Thus, other
mechanisms may also contribute to the induction of these processes in neurons.
In addition to its role in monitoring mitochondrial dynamics [7], PINK1
might directly affect mitochondrial motility since it also forms a complex with Miro
and Milton [8]. The latter proteins are known to recruit kinesin to the mitochondria
and promote motility along microtubule tracks [9]. Recently, an ROSindependent, redox dependentprotein termed HUMMR (hypoxia upregulated
mitochondrial movement regulator) was discovered that also interacts with Milton
and Miro to influence mitochondrial movement and direction [55]. Knockdown of
HUMMR decreased anterograde movement of mitochondria and increased
retrograde movement [55]. Given that MPP+-disrupted mitochondria exhibited
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decreased anterograde and increased retrograde movement and that only the
redox protectants NAC and GSHEE prevented these axonal effects, it may be
possible that HUMMR, in conjunction with PINK1/Milton and Miro, plays a role in
this process. Although MPP+-decreased m may be sufficient to reduce and
alter mitochondrial movement, whether these or other transport-associated
proteins play ancillary roles awaits future studies.
A recent study suggests that somal and dendritic DA mitochondria occupy
only 40% of the area of non-DA mitochondria [43]. Our cross-sectional
measurements of mitochondria in DA axons versus non-DA axons mirror these
results, with DA mitochondria being only 40% of the size of their non-DA
counterparts (Table 4.2). Most importantly, axonal DA mitochondria exhibit an
instantaneous velocity that is almost three times slower than non-DA
mitochondria (Table 4.2). The validity of these observations is underscored by
the use of two different mechanisms to measure mitochondrial properties (MTR
and mtDendra2) (Table 4.2) with essentially the same results. Moreover, since all
measurements were taken from within the same axonal fields, even if absolute
numbers were affected by experimental conditions, the actual results are relative
to each other. Presumably, this reflects inherent differences in DA axonal
mitochondria themselves; perhaps a unique outer membrane protein interacts
with a scaffolding protein that, in turn, binds to a slower motor. Alternatively, DA
axons might be slightly narrower, slowing larger organelles and potentially
contributing to their smaller size. Thus, in addition to producing a transmitter
prone to oxidation [45] and reliance upon L-type Ca2+ channels that appear to
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drain ATP resources [56], DA neurons might also be less effective at delivering
mitochondria to sites of high energy usage such as synapses.
Redistribution of mitochondria away from sites of high ATP usage would
lead to axonal impairment, loss of synaptic connectivity, and hence loss of
function. Although mitochondrial redistribution may not be the sole trigger of
axonal dysfunction, it occurs early and is consistent with increased mitochondrial
staining in the cell body (data not shown). This study, together with the large
amount of evidence suggesting that PD is associated with axonal “dying-back,”
underscores the necessity of developing therapeutics aimed at axons as well as
cell bodies so as to preserve circuitry and function. Because NAC pretreatment
not only prevented mitochondrial dysfunction but also preserved neurites and cell
bodies, NAC or drugs like it may serve a future therapeutic role.
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Table 4.1 - Effects of substrates, inhibitors, and
anti-oxidants on MPP+-disrupted mitochondrial
axonal transport.
Motile mitochondria (%)
Control
MPP+

18.41 ± 3.62
8.25 ± 1.34 a

+ Glucose

6.19 ± 1.26

+ Csp3I- II

10.96 ± 2.58

+ Gö6976

6.16 ± 3.42

+ EGTA

4.80 ± 2.70

+ SP600125

4.63 ± 0.63

+ MnTBAP

9.49 ± 1.51

+ NAC

18.62 ± 3.53b

+ GSHEE

15.49 ± 3.10b

Numbers are mean ± SEM, ap<0.05 compared to Control,
b

p<0.05 compared to MPP+. Concentration: MPP+ (2 µM),

Glucose (20 mM), Csp3I-II (Caspase-3 inhibitor II, 5 µM),
Gö6976 (500 nM), EGTA (2.5 mM), SP600125 (10 µM),
MnTBAP(100 µM), NAC (N-acetylcysteine, 2.5 mM),
GSHEE (5 mM).
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Table 4.2 - DA axons exhibit unique mitochondrial and vesicular
characteristics
DA

non-DA

Density‡

8.89 ± 0.86

9.50 ± 0.82

Moving particles‡

1.93 ± 0.22

2.49 ± 0.24*

MTR

0.28 ± 0.05

0.79 ± 0.07**

mtDendra2

0.30 ± 0.02

0.61 ± 0.11**

MTR

1.07 ± 0.12

2.52 ± 0.11**

mtDendra2

0.94 ± 0.06

2.17 ± 0.47*

58.5 ± 3.22

65.2 ± 4.08

Moving particles‡

3.93 ± 0.30

5.71 ± 0.63*

Speed (µm/s)

0.56 ± 0.05

0.52 ± 0.03

Moving particles‡

6.35 ± 1.22

6.79 ± 0.48

Speed (µm/s)

0.12 ± 0.01

0.14 ± 0.01

Speed (µm/s)

Cross area (µm2)

Ψm (AU)
Synaptic vesicles

All particles

‡

(#/100 µm). Numbers are mean ± SEM, *p<0.05, **p<0.001 compared to DA
neurons. For MTR studies, 33 dishes from 11 independent experiments were
evaluated; for mtDendra2 studies, eight dishes from four independent
experiments were assessed. For synaptic vesicles, three dishes from three
independent experiments were assessed. When measuring all particles, seven
dishes from seven independent experiments were measured. In all cases 3-5
axons per dish were analyzed.
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Table 4.3 - MPP+ did not affect mitochondrial number, speed or size in nonDA axons
Control

MPP+

Moving particles (#/100 µm)
MTR

2.49 ± 0.24

2.01 ± 0.23

mtDendra2

1.92 ± 0.61

2.48 ± 0.14

MTR

0.79 ± 0.07

0.71 ± 0.09

mtDendra2

0.61 ± 0.11

0.65 ± 0.19

MTR

2.52 ± 0.11

2.36 ± 0.19

mtDendra2

2.17 ± 0.47

2.57 ±0.46

Speed (µm/s)

Cross area (µm2)

Numbers are mean ± SEM. For MTR studies, 33 dishes from 11 independent
experiments were evaluated; for mtDendra2 studies, eight dishes from four
independent experiments were assessed. In all cases 3-5 axons per dish were
analyzed.
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Figure 4.1 - Neurite degeneration, microtubule disruption, and autophagy
precede DA cell death following MPP+ treatment. (A) Dissociated DA neurons
were treated with 1 M MPP+ for indicated times and then fixed and
immunostained with rabbit polyclonal anti TH antibody. (B) Quantification of THpositive cell bodies and neurites remaining after toxin treatment. Numbers of THpositive cell bodies and neurites were counted using Stereo Investigator.
Neurites were significantly reduced after 12 hours of treatment, whereas the
number of cell bodies did not significantly change until 24 hours. Data denote the
mean + SEM of representative determinations made in three independent
experiments. (C) Integrity of microtubule tracks was assessed by measuring
tubulin fragmentation before and after MPP+ treatment. Compartmented axons
(described below) were fixed after 3, 6, and 24 hours of MPP+ treatment and
stained with antibodies directed against AcTub and TH. Beading is seen as early
as 6 hours (insert, arrowheads) and fragmentation at 24 hours (arrow). (D) THpositive axons with fragmented acetylated tubulin were quantified. One hundred
to three hundred TH-positive axons were counted per dish and three dishes were
counted per group. (E) Integrity of microtubule tracks was also assessed by
transfecting tubulin-mCherry into DA/GFP cultures at DIV6. Following the
addition of 2 mM MPP+, live images were acquired at the indicated times. (F)
Tubulin intensity was expressed as percentage control. Mean + SEM made in
three independent experiments, *p0.05, **p0.001, compared to 0 hours; #p0.05,
compared to DA at 24 hours. (G) Autophagy was assessed by introducing a
GFP-tagged LC3 expression clone at DIV6 and treating DA neurons 1 day later
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with 2 M MPP+.The formation of LC3-positive granules was measured as
indicated by immunostaining. Lower panels show LC3 fluorescence within THpositive axons before (top) and after (bottom) toxin treatment. For clarity, only
LC3 fluorescence in axons is shown. (H) The number of TH-positive neurons with
at least three LC3-GFP granules was counted and expressed as percentage of
all neurons that were both TH positive and LC3-GFP positive, regardless of
whether the LC3-GFP signal in these neurons was diffuse or punctuate. Mean +
SEM in three independent experiments, *p0.05. In all bar graphs, hatching
indicates toxin treatment. Scale bars: (A,C,E) 10 m (G) 1 m.
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Figure 4.2 – MPP+ rapidly decreases mitochondrial movement in DA axons
as shown by mtDendra2. (A) Diagram of microchamber device. (B) Transmitted
light image of segregated axons derived from DIV12 DA/GFP cultures in the top
panel, GFP fluorescence in the middle panel, and the merged image in the
bottom panel showing TH-positive and TH-negative axons in same field. (C)
Immunostaining of the axonal side with TH, the axonal marker Tau, and the
dendritic marker MAP2. Tau but not MAP2 positive processes is present on
axonal side. Scale bar, 10 m. (D) mtDendra2 colocalizes with TMRE. Despite
presence of nonconverted mtDendra2, DA axon is easily identified. (E) Axonal
movement of mitochondria. Mitochondria labeled with mtDendra2 were imaged
for 5 min at 5 sec intervals after 30 min incubation with and without 2 M MPP+.
For consistency, mitochondrial measurements were assessed near the axon
terminal at least 2 mm away from the cell bodies. Resulting kymographs are
shown below. (F) Number of moving mitochondria per 100 m length of axon
was calculated. (G) Speed was calculated as described in Materials and
Methods. (F,G) Mean + SEM, *p0.05, total of 17 (control) and 14 (MPP+-treated)
axons derived from at least 7 dishes in 3 independent experiments. The
anterograde speed (Antero) was decreased and the retrograde speed (Retro)
increased as early as 30 min after MPP+ treatment. Scale bars: (B-D) 10 m.
Hatching indicates toxin treatment.
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Figure 4.3 – MPP+ rapidly decreases mitochondrial movement in DA axons
as shown by MitoTracker Red. (A) Axonal movement of mitochondria.
Mitochondria were labeled with 25 nM MTR and imaged for 5 min at 5 sec
intervals after 30 min of incubation with and without 2 M MPP+. Mitochondrial
measurements were assessed as described in Figure 2. Resulting kymographs
are shown below. (B) Total and moving mitochondria were counted and the rate
of motile mitochondria was calculated. (C) Speed was calculated as described in
Materials and Methods. (B,C) Mean + SEM, *p0.05, total of 114 (control) and 175
(MPP+-treated) axons from 15 and 28 dishes in 13 independent experiments.
Total length of control and MPP+-treated axons sampled were 10,716 and 16,732
m, respectively, and the total numbers of mitochondria examined were 1762
and 2632, respectively. The anterograde speed (Antero) was decreased and the
retrograde speed (Retro) increased as early as 30 min after MPP + treatment.
Hatching indicates toxin treatment.
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Figure 4.4 – MPP+ does not affect axonal movement of synaptic vesicles.
Dissociated DA/GFP cultures were transduced with Syn-Cer lentivirus at DIV2.
Vesicular movement was assessed on DIV12–13 before and after toxin
treatment. (A) Although some vesicles were clumped and appeared to overlap
mitochondria, individual vesicles labeled with Syn-Cer (arrows) were also
visualized adjacent to mitochondria labeled with MTR (arrowheads). (B)
Vesicular movement was observed for 5 min before and after 30 min of
incubation with and without 2 M MPP+. Because of the smaller size of vesicular
particles and the relative “dimness” of the cerulean emission, tracks of moving
particles are shown below for clarity. (C,D) Quantification of moving particles (C)
and speed (D) were determined as described in Materials and Methods. Scale
bar: 10 m. Mean + SEM, ns, nonsignificant, total of 25 (control) and 38 (MPP+treated) axons from 4 and 5 dishes in 4 independent experiments. Total lengths
of control and MPP+-treated axons sampled were 2247 and 3497 m,
respectively. Hatching indicates toxin treatment.
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Figure 4.5 - MPP+ rapidly leads to DA efflux. 3H-DA release assays were
performed exactly as we have previously described except that 10 min treatment
windows were used instead of 6 min [18]. (A) MPP+ dose response curve; EC50
for DA release is 0.42 ± 0.04 µM (mean ± SEM). (B) MPP+-mediated DA release
can also be assessed in segregated axons. Each chamber was briefly incubated
with 3H-DA, washed extensively with PBS and then treated with or without 1 µM
MPP+ for 10 min. Chambers were washed and then treated with 60 mM K+ to
release vesicular contents and finally lysed to assess remaining DA levels [18].
Top panel, high K+ releases 50-60% of intracellular DA levels in control cell
bodies and axons whereas, 1 µM MPP+ releases >95% (Bottom panel). Axononly chamber represented about 25% of transmitter levels in cell body chamber.
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Figure 4.6 - MPP+ rapidly depolarizes DA mitochondria. (A) Mitochondria in
axons from DA/GFP cultures were labeled with 25 nM TMRE and then assessed
before and 30 min after MPP+ treatment. Scale bar: 5 m (B) MPP+ led to
significant differences in ΔΨm as measured in arbitrary units (AU; arrows). (C)
Cross sectional areas of mitochondria labeled with MTR were measured before
and after toxin treatment using Image J particle analysis. Hatching indicates toxin
treatment. (Mean ± SEM of

representative determinations

independent experiments, **p<0.001)
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Figure 4.7 - NAC protects DA cell bodies and neurites from MPP+-induced
degeneration. (A) Dissociated DA neurons were pretreated with 2.5 mM NAC for
18 hours, treated with 2 µM MPP+ for 24 hours and then fixed and
immunostained with rabbit polyclonal anti-TH antibody. Scale bar: 10 m (B)
Quantification of TH-positive cell bodies and neurites. Cell bodies and neurites
were significantly protected by NAC. (Mean ± SEM from three independent
experiments, *p<0.05, compared to Control, #: p<0.05, ##: p<0.001, compared to
MPP+)
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Chapter 5

S

Wld protects dopaminergic axons from MPP+-induced changes in
mitochondrial transport

This manuscript is in preparation for publication
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Abstract
An emerging hypothesis in Parkinson’s disease (PD) is that dopaminergic
(DA) neurons degenerate through a “dying back” axonopathy wherein
degeneration begins in the distal axon and progresses over time towards the cell
body. Impaired axonal transport also appears to play an early, pivotal role in PD.
Thus processes that delay axonal transport dysfunction and/or axonal
degeneration might slow PD progression. Previously, our lab has found that the
WldS mouse mutant (“Wallerian degeneration-slow”), which exhibits delayed
axonal degeneration after peripheral axonopathy, also protects DA terminal fields
from the PD-mimetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in
vivo. To understand the mechanisms underlying WldS-mediated axonal
protection, we utilized compartmented chambers that enabled us to segregate
axons from cell bodies and dendrites. Using these devices, we found that MPP +
impaired mitochondrial in DA axons and that WldS rescued MPP+-mediated
impairment of mitochondrial transport in DA axons. Mechanistically, this appears
to be the result of WldS-mediated protection from toxin-induced loss of
mitochondrial membrane potential. These results extend WldS protection to CNS
DA axons and suggest that WldS confers a gain-of-function phenotype that
attenuates mitochondrial dysfunction. This study also underscores the necessity
of developing therapeutics aimed at axons as well as cell bodies in order to
preserve circuitry and function.
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5.1

Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative

disorder in the U.S. The cardinal motor symptoms of PD include resting tremor,
bradykinesia, rigidity, and abnormal gait [1-2]. These symptoms appear after 5070% [3-4] of striatal dopamine (DA) levels have been depleted and 30-50% [5-6]
of the DA cells in the substantia nigra (SN) have died. Given that the severity of
PD symptoms correlates better with loss of striatal DA [5] and because many
postmortem studies show widespread axonal pathology [7,8], early axonal
dysfunction may play a significant role in PD.
Data from animal models of PD support the notion that DA axons are
compromised prior to cell body loss. For example, transgenic mice expressing
the PD-linked R1441G leucine-rich repeat kinase2 (LRRK2) mutation exhibited
decreased DA terminal fields and increased dystrophic processes yet only
modest changes were seen in the number of their SN neurons. [7]. In addition,
mutant -synuclein proteins accumulate in the cell soma when overexpressed in
cortical neurons suggesting that these mutants exhibit reduced axonal transport
[8]. Support for this notion comes from data showing that vesicle-associated synuclein binds to the microtubule motor proteins kinesin and dynein [9], thereby
affecting microtubule-dependent axonal transport. Another PD-linked gene,
PINK1, a mitochondrially targeted kinase, can also form a complex with Miro and
Milton [10], proteins known to recruit kinesin to the mitochondria and promote
motility along microtubule tracks [11]. Finally, in some but not all model systems
[12-13], the PD associated ubiquitin ligase, Parkin, is recruited to mitochondrial
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membranes by stabilized PINK1. Through unknown mechanisms, Parkin then
recruits autophagy machinery to the mitochondria [14] (mitophagy) presumably to
clear dysfunctional organelles [15]. If the clearance system is overwhelmed,
axonal degeneration may ensue [16].
Environmental toxins mimicking PD such as N-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) or its active derivative, 1-methyl-4-phenylpyridinium
(MPP+) have also been shown to disrupt axonal function. For example,
Herkenham et al., observed marked reductions of dopaminergic axons prior to
the loss of nigral cell bodies following acute MPTP administration in monkeys
[17]. Similarly, Meissner et al. reported an 80% loss of both the dopamine plasma
membrane transporter (DAT) and DA levels in the macaque striatum following
chronic MPTP delivery whereas only a 43% loss of DA cells was observed in the
SN [18]. DA terminal loss is also the earliest event in murine MPTP models [19].
Using both the acute and chronic MPTP paradigms, Li and colleagues observed
~25% cell body loss after treatment whereas DA terminals were decreased by
~65-70% in either model [20]. Finally, a recent study reported a profound
decrease (73%) in striatal DA following MPTP treatment whereas only a 9%
decline of SN cells was observed [21]. In this same study, the GDNF receptor,
RET, rescued the cells but not the terminal fields, re-confirming the basic
observation that axons and cell bodies constitute separate compartments. These
findings support the hypothesis that nigral neurons degenerate through a “dying
back” axonopathy in which degeneration begins in the distal axon and proceeds
over time towards the cell body [22-23].
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The question arises then as to what factor or signaling system might
rescue axons from degeneration? One serendipitous protein is the spontaneous
mouse mutant, Wallerian degeneration slow (WldS). WldS delays axonal
degeneration about 10-fold from a wide variety of genetic and toxin-inducing
stimuli in the peripheral nervous system (PNS) [24] and in several central
nervous system (CNS) models of degeneration including animal models of PD
[25-26]. For example, we have shown that WldS rescues 85% of DA axons for at
least 7 days post MPTP treatment in vivo [27]. Not only does WldS protect DA
terminal fields in vivo, the same holds true in vitro as demonstrated in Chapters 2
and 3. Specifically, dissociated DA neurons prepared from WldS mice were also
significantly protected from MPP+. WldS itself is a chimeric protein composed of
the N-terminal 70 amino acids of the ubiquitination factor Ube4b followed by a 18
amino acid linker region and the entire sequence of Nmnat1, a key enzyme in the
biosynthesis of NAD+ [28]. In contrast to peripheral model systems [24], we saw
that only the entire WldS fusion protein protected DA neurites, whereas Nmnat1,
cytoplasmically targeted Nmnat1 or Nmnat3 did not (Fig. 2.3 and 3.2).
Surprisingly, WldS constructs mutagenized for NAD+ synthesizing activity were
just as effective as non-mutagenized WldS constructs (Fig. 2.5). These data
suggest that increased NAD+ may not underlie the ability of WldS to rescue DA
neurites from toxin effects. Given these significant attributes of WldS,
understanding how the WldS fusion protein prevents axon degeneration is an
important step towards identifying an intervention that would leave axons intact.
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In order to more easily test the effects of WldS on DA axons we crossed
WldS mice with genetically engineered mice expressing GFP in DA neurons
(DA/GFP). The resulting WldS/DA/GFP mice were plated in microchamber
devices that segregated DA axons from DA cell bodies. As shown previously
[29], wild type mice rapidly lost mitochondrial motility in DA axons when
challenged with MPP+. In contrast, WldS protected DA axons from MPP+-induced
disruption in mitochondrial axonal transport, possibly through a direct action on
the mitochondria.

5.2

Materials and methods

All of the methods and materials for making the cell cultures and
microchamber devices, imaging and quantifying axonal transport, measuring
dopamine uptake and release, quantifying mitochondrial membrane potential
(m) and length, measuring autophagy, and performing statistical analyses for
these set of experiments were performed exactly as described for Chapter 4.
Experiments

were

mesencephalic

done

cultures

EGFP)DJ76GSAT

and

on

both

prepared

DA/GFP
from

and

WldS-DA/GFP

embryonic

day

14

C57Bl/OlaHsd-WldS-Tg(TH-EGFP)DJ76GSAT

murine
Tg(THmice,

respectively (Gene Expression Nervous System Atlas, National Institutes of
Health, Bethesda, MD and Harlan, Bichester, UK).
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5.2.1 Western Blotting
Western blotting was done as described in Chapters 2 and 3, with the
exception that PVDF membranes were probed with a mouse acetylated tubulin
antibody (Sigma-Aldrich, Saint Louis, MO). As a loading control, PVDF
membranes were also probed with mouse monoclonal anti-actin antibody
(Sigma-Aldrich) followed by an HRP-linked mouse secondary antibody (Jackson
Immunoresearch, West Grove, PA).

5.2.2 Immunohistochemistry
To determine where WldS is expressed in DA axons, WldS primary
mesencephalic cultures were plated in microchamber devices, fixed and then
stained with rabbit WldS antibody (1:500, gift of M.P. Coleman) and Alexa488
anti-rabbit antibody (1:500, Molecular Probes, Carlsbad, CA). In some cases,
axons were incubated with 25 nM MitoTracker Red (MTR; Invitrogen, Carlsbad,
CA) prior to fixation. To determine acetylated tubulin levels specifically in DA
axons, primary midbrain cultures plated in microchamber devices were fixed and
stained with mouse acetylated tubulin (1:1000, Sigma-Aldrich) and Cy3 antimouse antibodies (1:500, Molecular Probes, Carlsbad, CA).

5.2.3 Fragmentation of axons
Fragmentation of axons was assessed by sampling five non-overlapping
fields in the axonal part of the chamber. The number of DA/GFP axons was
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counted using an unbiased grid system in ImageJ. The degree of change in axon
structure was quantified as: (Number of fragmented axons) / (Number of total
axons).

5.3

Results

5.3.1 WldS prevents MPP+-induced changes in axonal structure
We have previously reported that DA terminal fields but not cell bodies of
WldS mice are protected against MPTP injury [27] in vivo and MPP+ toxicity in
vitro (Fig. 2.1). To confirm and extend these observations in our modified
microchamber system, primary mesencephalic cells obtained from both DA/GFP
and WldS-DA/GFP mice were grown in compartmented chambers and treated
with 2 M MPP+ on DIV14. Chambers were subsequently fixed at various time
points and examined for axonal integrity using GFP fluorescence as a relevant
indicator of DA axons. Like MPTP treated WldS mice [27] or MPP+-treated
dissociated DA neurons (Fig. 2.1), DA axons from DA/GFP/WldS mice were
significantly protected from toxin treatment at all time points, most prominently at
12 h (Fig. 5.1A,B). Thus, in vitro as in vivo [23], WldS protects DA axons from
MPTP/MPP+ toxicity.
Studies in cultured cerebellar granule cells have shown that WldS cultures
have higher baseline levels of acetylated tubulin compared to WT cultures [30].
To determine if WldS DA neurons exhibit higher levels of microtubule acetylation,
we either stained DA axons with anti-acetylated tubulin or prepared lysates from
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midbrain cultures for western blotting. Neither immunocytochemical techniques
(Fig. 5.1C) nor western blots (Fig. 5.1D,E) detected differences in acetylated
tubulin levels between WT and WldS cultures. Thus, differences, if any, are not
apparent in WldS compared to wild type DA axons or cultures

5.3.2 WldS protein is present in DA mitochondria
Many studies have shown that the WldS fusion gene is primarily localized
in the nucleus [31]. This is also true in DA neurons in the SN [27]. Despite the
abundance of WldS in the nucleus, it can also be found in other locations
including axons [32]. “Extranuclear” WldS is reportedly associated with small
membranous structures including mitochondria [33]. To determine the subaxonal
expression pattern of WldS, we labeled compartmentalized axonal mitochondria
with MTR and then fixed and stained for WldS with the Wld18 antibody. WldS was
axonally distributed in pleo-morphic globular organelles which significantly
overlapped with MTR (56.14 + 15 % overlap) (Fig. 5.2). Other studies have not
identified any overt structural differences in mitochondria derived from WT or
WldS mice [34-35]. In agreement with these findings, we did not see any
differences in baseline mitochondrial density, number of moving mitochondria,
mitochondrial velocity, mitochondrial length, or m between DA/GFP and WldSDA/GFP DA axonal mitochondria (Table 1). These data indicate that extranuclear
WldS is readily distributed to DA axons where it is associated with mitochondria
but does not outwardly change any of their parameters.
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5.3.3 WldS prevents MPP+-induced changes in axonal mitochondrial
transport
Recently, we demonstrated that MPP+ rapidly decreases mitochondrial
transport in DA axons [29]. Because WldS significantly co-localized with axonal
mitochondria (Fig. 5.2), we tested whether mitochondrial transport was altered in
WldS-DA/GFP axons. As we previously reported, MPP+ decreased the numbers
of moving mitochondria in DA/GFP axons by 50% within 30 min of treatment (Fig.
5.3A,B). We also confirmed in DA/GFP axons that MPP+ treatment decreased
the number and speed of moving mitochondria in the anterograde direction but
increased speed in the retrograde direction (Fig. 4.3) [29]. In contrast, numbers
of moving mitochondria in WldS-DA/GFP axons were not affected by MPP+
treatment nor were there any differences in their anterograde or retrograde
motility (Fig. 5.3A,B). Similarly, no change in mitochondrial velocity was
measured following MPP+ treatment in either the anterograde or retrograde
direction in WldS-DA/GFP cultures (Fig. 5.3A,C). Thus WldS prevents the rapid
and directed effect of MPP+ on DA axonal mitochondria.
To determine whether WldS had an effect on other types of organelles
particularly

synaptic

microchamber

vesicles,

devices

were

DA/GFP
transduced

and

WldS-DA/GFP

using

a

lentivirus

cultures

in

expressing

synaptophysin fused in frame with cerulean (Syn-Cer). We did not observe any
significant difference between DA/GFP and WldS-DA/GFP axons in terms of the
number of moving Syn-Cer particles per 100 m length of axon (2.88 + 0.17 and
3.02 + 0.44, respectively). Not surprisingly, no significant difference was apparent
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in the velocity of the Syn-Cer particles in DA/GFP and WldS-DA/GFP cultures
(0.47 + 0.02 m/sec and 0.41 + 0.08 m/sec, respectively) as well. Despite
MPP+-induced changes in mitochondrial axonal transport, (Fig. 5.3A,B) [29],
MPP+ did not affect synaptophysin motility and velocity in wild type or WldS
cultures (Fig. 5.3D,E), indicating that the effect of WldS is specific for
mitochondria.

5.3.4 WldS prevents MPP+-induced decreases in axonal mitochondrial
membrane potential
Because MPP+ leads to a rapid loss of m, in DA axons [18], we tested
whether WldS affected that process. Compartmentalized DA/GFP and WldSDA/GFP

axons

were

labeled

with

the

sensitive

m

indicator

tetramethylrhodamine ethyl ester (TMRE) before acquiring baseline images. After
30 min of toxin treatment, m was significantly reduced in DA/GFP but not
WldS-DA/GFP axonal mitochondria (Fig. 5.4A,B). Similarly there were no
significant differences in the size of WldS-DA/GFP mitochondria following MPP+
treatment (not shown). Thus, MPP+ rapidly depolarized DA/GFP mitochondria but
not WldS-DA/GFP.
To test whether WldS also protects DA mitochondria from other types of
depolarizing agents, we treated DA/GFP and WldS-DA/GFP axons with carbonyl
cyanide m-chlorophenyl-hydrazone (CCCP), which depolarizes mitochondria by
acting as an uncoupler [36]. DA/GFP and WldS-DA/GFP axons were labeled with
TMRE and images were acquired at baseline as well as at 15 and 30 minutes
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after the addition of CCCP. CCCP reduced m in both DA/GFP and WldSDA/GFP axonal mitochondria at both time points examined (Fig. 5.4C,D), but
there was a significant attenuation observed in WldS DA mitochondrial axons at
30 minutes. Taken together, these results show that WldS attenuates processes
that alter mitochondrial membrane potential such as blocking complex I (MPP+)
or uncoupling membrane potential (CCCP)

5.3.5 WldS protects DA neurons against MPP+-induced autophagy
Decreases in m can induce mitophagy (autophagy of mitochondrial
organelles) [32]. Given that we [18] and others [33] have shown that MPP+
induces autophagy in DA neurons, we tested whether WldS could prevent
autophagy in this model system. Using GFP-labeled LC3 (microtubuleassociated protein 1, light chain 3; also known as ATG8), as a frequently used
marker of autophagy, we confirmed our previous observation that LC3-GFP
puncta were visible as early as 3 hours after MPP + treatment [29] (Fig. 5.5A). In
contrast, WldS cultures transduced with LC3-GFP maintained the normal diffuse
cytoplasmic distribution even after MPP+ treatment (Fig. 5.5). These data are
consistent with the evidence that WldS prevents MPP+-induced mitochondrial
membrane depolarization and this in turn prevents the induction of mitophagy.

5.4

Discussion
Numerous studies suggest that axonal dysfunction precedes cell body

death in many neurodegenerative disorders, especially PD. Halting or delaying
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axonal degeneration would allow DA axons to stay “wired up” and hence,
functional. Because WldS dramatically rescued DA terminal fields from MPTP in
vivo [27] and since WldS also protects DA neurites in vitro (Fig. 2.1), we used
optical, cellular and molecular techniques to demonstrate that WldS protects DA
axons by maintaining m, mitochondrial motility, and mitochondrial velocity such
that autophagic processes are not activated.
What is the mechanism by which WldS protects DA terminals? Although
many studies have emphasized that both Nmnat1 and cytoplasmically re-directed
Nmnat can protect axons in many peripheral model systems, few studies have
tested how WldS protects DA neurons from PD-linked genes and/or toxins.
Studies on peripheral nervous system models attribute the protective phenotype
of WldS to its Nmnat portion. In vitro studies have shown that overexpression of
Nmnat1 by itself protects axons from many mechanical, genetic or toxin-induced
injuries [24, 37]. However, transgenic animals expressing nuclear Nmnat1 are
less neuroprotective than WldS [38-39]. In part, this might be due to where
Nmnat1 is expressed [24] since cytoplasmically [40] or axonally targeted Nmnat1
[33] in vivo was equally if not more effective than WldS at protecting axons
against injury. Interestingly, in either case Nmnat1 was expressed at higher
levels in the mitochondrial fraction compared to nuclear Nmnat1 [33, 40].
Nmnat3, a mitochondrially expressed isoform of Nmnat, also showed comparable
levels of protection to WldS when expressed in vivo, unlike native Nmnat1 [39].
Even the WldS fusion protein was more effective in vivo when it was targeted to
the cytoplasm and it also showed higher levels of expression in the mitochondria
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than native WldS [32]. Although we used the original WldS animals (albeit crossed
with DA/GFP), our study shows that extranuclear WldS partially colocalizes with
axonal DA mitochondria,

attenuating MPP+-induced changes in m,

mitochondrial motility and mitochondrial velocity. Thus, the present findings are
consistent with the observations that WldS might regulate or affect an important
mitochondrial process.
Data supporting this idea comes from a differential proteomics approach
comparing WT and WldS striatal synaptosomes [34]. Sixteen proteins were found
to be differentially expressed, eight of which were localized to the mitochondria.
These included the VDAC2, a pore forming protein in the outer mitochondrial
membrane which essentially serves as a metabolite exchanger [41]. The latter,
although not part of the mPTP is thought to play a role in regulating it [42]. Of the
three known VDACs each has a unique phenotype. For instance, VDAC2 inhibits
apoptosis whereas VDAC1 is an activator of apoptotic processes [43]. Given the
complexity of their protein structure and the numerous isoform-specific proteinprotein interactions, there might be many target points for WldS/VDAC2
interactions.

Nonetheless, since DA synapses would comprise a significant

proportion of striatal synaptosomal preparations, the changes in mitochondrial
proteins in WldS versus WT re-enforce the notion that WldS might be acting
directly at the level of the mitochondria to prevent axonal dysfunction.
Mitochondria undergo complex fission and fusion processes in part to
ensure a healthy pool of organelles [44]. Towards this end it is thought that
depolarized mitochondria are quickly culled from the pack and marked for
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destruction, possibly through the stabilization of PINK1 on the outer
mitochondrial membrane followed by the recruitment of Parkin and other
mitophagic components [45]. Earlier studies done in wild type or WldS superior
cervical ganglion (SCG) cultures found that, as expected, WldS protected SCG
neurites from vinblastine treatment. But for the first time, it also showed that WldS
prevented a highly significant loss of m which occurred in wild type cultures
[35]. In other studies using sciatic nerve preparations, axon degeneration was
ascribed to activation of the mitochondrial permeability transition pore (mPTP)
[46]. Opening of the mPTP is thought to trigger m, ROS, loss of ATP, and
release of pro-apoptotic factors, amongst other things [47]. In this same sciatic
nerve study, WldS prevented the activation of mPTP after axons were cut but was
unable to protect axons from pharmacological agents directly activating the pore
[46]. These results prompted Barrientos et al. to propose a model in which WldS
acts upstream of the mitochondria to prevent the opening of the mPTP [46].
Barrientos et al. also showed that both pharmacologic and genetic
manipulation of cyclophilin D, a functional component of the mPTP, were able to
prevent axon degeneration [46]. Recently Thomas et al. reported that cyclophilin
D knockout mice were significantly resistant to MPTP toxicity, raising the
possibility that this mechanism might hold true for this PD-linked toxin as well.
However, several caveats for this idea exist. The authors found that knocking out
cyclophilin D was ineffective against subacute or chronic MPTP models and only
partially effective at rescuing SN neurons in the acute model. Although it
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appeared that there was some preservation of DA terminal fields, that area most
relevant to this study, densitometry was also not done in these animals [48].
Perhaps the most direct question is whether MPP + activates the mPTP in
the dissociated culture system. Earlier experiments using bongkrekic acid and/or
cyclosporine A to prevent mPTP opening following MPP + did not rescue DA
neurons from cell death [Lotharius and O’Malley, unpublished observation]. It will
be important to repeat these experiments using our current model system to see
whether cyclosporine A prevents MPP+-induced depolarization of DA axonal
mitochondria.
This work and our previous work show that MPP + rapidly inhibits the
motility of DA mitochondria [29]. Despite the MPP+-induced decrease seen in
m, increasing ATP levels, blocking ROS production or JNK, PI3K or PKC
pathways, or preventing rises in cytoplasmic calcium levels did not rescue
mitochondrial motility. To date, the only pharmacologic agents that prevented
MPP+-induced mitochondrial immobility were

N-acetylcysteine (NAC) and

membrane permeable GSH [29]. Given the prevalence of redox-sensitive
proteins in the mitochondria and the close connection between redox balance
and membrane potential [49], redox regulation of depolarization might facilitate
interactions between the bioenergetic membranes and homeostatic processes
such as mitophagy. WldS could potentially work at the level of the mPTP by
blocking pore activation or at the level of the mitochondrial thioredoxin/ or
glutaredoxin/ reductase systems to maintain a reduced state [50]. Since
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cyclophilin D itself is regulated by redox potential, mPTP could be indirectly
strengthened via a WldS effect on redox potential.
Although maintenance of mitochondrial function may not be the sole
trigger of axonal dysfunction, our data shows that it plays an early and pivotal
role in the degeneration of axons. This study, together with the large amount of
evidence suggesting that PD is associated with axonal “dying-back,” underscores
the necessity of developing therapeutics aimed at axons as well as cell bodies so
as to preserve circuitry and function. Understanding how WldS protects axons is
important in designing potential interventions that can delay or halt axonal
dysfunction and ensuing disease progression.
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Table 5.1 - WT and WldS have similar mitochondrial characteristics
DA

Non-DA

WT

WldS

WT

WldS

8.89 + 0.86

8.43 + 0.48

9.5 + 0.82

10.08 + 0.59

100 mm

1.93 + 0.22

2.00 + 0.19

2.49 + 0.24*

2.78 + 0.19*

Speed (mm/s)

0.28 + 0.05

0.23 + 0.20

0.79 + 0.07**

0.87 + 0.06**

Length (mm)

1.19 + 0.04

1.17 + 0.09

2.28 + 0.12

2.7 + 0.19

m(AU)

50 + 8.37

49.55 + 10.3

55.14 + 9.14

48.70 + 6.32

Density
Moving particles/

Mean + SEM, total of 40 (control) and 82 (MPP+-treated) axons derived from 8
independent experiments, *p<0.05, **p<0.01
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Figure 5.1 - WldS prevents changes in axonal structure after MPP+. (A)
Integrity of DA/GFP and WldS-DA/GFP DA axons was assessed before and after
MPP+ treatment. Compartmented axons were fixed after 12, 24, and 48 hours of
MPP+ treatment. (B) Fragmentation of DA axons was quantified. Mean + SEM
made in three independent experiments, *p<0.05, **p<0.001. (C) Levels of
acetylated tubulin (Ac-tub) were assessed by staining DA/GFP and WldSDA/GFP DA axons with acetylated tubulin antibody. No significant difference in
baseline acetylated tubulin levels was evident between WT and WldS axons. (D)
Western blot shows similar expression levels of acetylated tubulin in lysates from
WT and WldS primary mesencephalic cultures. (E) Quantification of the western
blots done on cell lysates from three independent experiments, Mean + SEM.
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Figure

5.2

-

WldS

partially

colocalizes

to

axonal

mitochondria.

Sublocalization of WldS was assessed by labeling mitochondria with MTR and
staining WldS DA axons with Wld18 antibody. Approximately 50% colocalization
of Wld18 staining and MTR signal was observed (arrows).
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Figure 5.3 – WldS protects against MPP+-induced changes in mitochondrial
axonal transport. (A) WldS-DA/GFP DA mitochondria labeled with MTR were
imaged for 5 min at 5 sec intervals after 30 min incubation with and without 2 M
MPP+. For consistency, mitochondrial measurements were assessed near the
axon terminal at least 2 mm away from the cell bodies. Resulting kymographs
are shown below. (B) Number of moving mitochondria per 100 m length of axon
was calculated. Mean + SEM, total of 40 (control) and 82 (MPP+-treated) axons
derived from 8 (control) and 16 (MPP+-treated) dishes in 8 independent
experiments. (C) Vesicular movement as measured using Syn-Cer was observed
for 5 min before and after 30 min of incubation with and without 2 M MPP+.
Quantification of moving particles was determined as described in Materials and
Methods. Mean + SEM. A total of 42 (control) and 80 (MPP+-treated) axons from
8 (control) and 16 (MPP+-treated) dishes in 8 independent experiments.
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Figure

5.4

-

WldS

prevents

MPP+-induced

decreases

in

axonal

mitochondrial membrane potential. (A) Mitochondria in axons from DA/GFP
and WldS-DA/GFP cultures were labeled with 25 nM TMRE and then assessed
before and 30 min after MPP+ treatment. (B) MPP+ led to significant differences
in ΔΨm in DA/GFP mitochondria but not in WldS-DA/GFP mitochondria. Mean ±
SEM of representative determinations from six independent experiments,
**p<0.001 (C) Mitochondria in axons from DA/GFP and WldS-DA/GFP cultures
were again labeled with 25 nM TMRE and then assessed before and 30 min after
2 m CCCP treatment. (D) CCCP led to decreases in ΔΨm in DA/GFP and WldSDA/GFP mitochondria at 15 and 30 minutes after addition of toxin, but WldSDA/GFP attenuated the effects of CCCP 30 minutes after treatment. Mean ±
SEM of representative determinations from six independent experiments,
*p<0.05.
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Figure 5.5 - WldS prevents mitophagy after MPP+. (A) Autophagy was
assessed by introducing a GFP-tagged LC3 expression clone at DIV6 and
treating DA neurons 1 day later with 2 M MPP+. The formation of LC3-positive
granules (arrow) was measured as indicated by immunostaining. Right panels
show LC3 fluorescence within TH-positive axons after toxin treatment. (B) The
number of TH-positive neurons with at least three LC3-GFP granules was
counted and expressed as percentage of all neurons that were both TH positive
and LC3-GFP positive, regardless of whether the LC3-GFP signal in these
neurons was diffuse or punctuate. Mean ± SEM in three independent
experiments, *p<0.05.
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Chapter 6

Conclusions and Future Directions
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6.1

Conclusions
Axonal dysfunction and impaired axonal transport may play a key role in

PD. This notion is dramatically supported by our earlier work showing that the
WldS fusion protein completely rescued DA terminal fields from in vivo MPTP
toxicity [1]. The current findings confirm and significantly extend these studies in
vitro exploring mechanisms underlying WldS actions against additional PD-linked
toxins. Our findings identify a novel role of WldS in DA axons that is independent
of its NAD+-synthesizing activity and further emphasizes a novel gain of function.
Moreover, our new observations point to a significant role of WldS in maintaining
or delaying changes in mitochondrial membrane bioenergetics .Finally, this
dissertation reinforces the notion that DA neurons are more susceptible in the
pathogenesis of PD due, in part, to unique characteristics of their mitochondria
that are smaller and slower than their counterparts.
Given the many studies showing that Nmnat at least partially protects
axons from a variety of insults both in the CNS but especially the PNS, our
studies showing that Nmnat1, Nmnat3 and cytoplasmically-targeted Nmnat1
cannot protect DA axons from two different types of parkinsonian mimetics were
surprising. Although it might be argued that the transduced levels of each variant
were insufficient to protect DA neurites, the fact that the same if not greater
numbers of DA neurons were transduced (Chapter 2), that expressed protein
levels were the same (Fig. 2.3), and most importantly, that the same lentiviral
preparations rescued DRG neurites from vincristine treatment, indicates that
insufficient Nmnat is not the cause. Most studies also suggest that Nmnat’s
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NAD+-synthesizing ability is essential in protecting axons [2-3], yet this did not
seem to be the case in DA neurites either (Fig. 2.5). Moreover, while exogenous
NAD+ did protect cell bodies and neurites against MPP+, its neuroprotective
effect was additive with that of WldS suggesting that it was acting through a
different mechanism (Fig. 2.8). Finally, even though WldS protected DA neurites
from 6-OHDA, neither Nmnat1 nor exogenous NAD+ did so, again suggesting
that the entire WldS fusion protein is required for protection of DA neurites. Taken
together, these findings argue that WldS plays a different role in DA neurons than
it does in certain CNS or PNS neurons.
What

is

different

about

DA

neurons?

Besides

producing

a

neurotransmitter that is prone to oxidation [4], DA neurons have long, thincaliber, poorly myelinated axons. Typically, such axons use more energy to
generate action potentials than more highly myelinated neurons [5]. Thus DA
axons may require more energy making them more susceptible to energy loss
than axons requiring less [5]. This idea is consistent with data demonstrating
preferential effects on DA neurons of inhibitors of mitochondrial complex 1 such
as MPP+ and rotenone and even 6-OHDA, leading to ROS, loss of m, and
eventually loss of ATP [6]. DA neurons also exhibit a greater dependence on Ltype Ca2+ channels than most neurons which can lead to deleterious amounts of
intracellular calcium and increased stress on mitochondria [7]. Moreover, DA
neurons have fewer mitochondria [8] and, as shown here [17], DA axonal
mitochondria are smaller and move along the axon slower than mitochondria in
non-DA neurons. These unique characteristics of DA neurons suggest that
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protection of these neurons may employ a different type of mechanism(s),
potentially one that protects DA mitochondria from bioenergetic challenges.
WldS is predominantly seen in the nucleus, but here, we present evidence
that the WldS protein partially colocalizes with DA axonal mitochondria (Fig. 5.2),
similar to what has been reported by others [9]. Thus, WldS can protect against
axonal degeneration by preserving mitochondrial function. In support of this, we
saw that WldS DA axonal mitochondria maintained their motility after MPP+
treatment. WldS also protected axonal DA mitochondria against MPP+-induced
decrease in mitochondrial membrane potential (m) and attenuated the effect of
carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) on m. In addition, WldS
neurites were protected against 6-OHDA, which our lab has previously reported
to cause ROS generation and a rapid decrease in m of DA neurons [10].
These results are consistent with data showing that WldS cultures maintain their
m and have intact neurites after vincristine treatment [11]. Taken together, our
findings and other studies underscore the role of mitochondria in the
neuroprotective phenotype of WldS.
So how does WldS protect DA axonal mitochondria? A recent study has
shown that WldS was able to regulate the mitochondrial permeability transition
pore (mPTP) and prevent calcium release, ATP loss, oxidative stress and
release of proteins involved in axonal degeneration in sciatic nerve explants [12].
In addition, the mPTP inhibitor, promethazine, was reported to prevent MPTPinduced loss of SN DA neurons [13]. Because CCCP and oxidative stress can
also induce mitochondrial permeability transition [14-15], one potential model is
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that WldS protects axons by inhibiting mPTP activation, mitochondrial
depolarization,

and

all

the

subsequent

complications

of

mitochondrial

dysfunction. WldS can potentially prevent opening of the mPTP in response to
toxin injury in two ways. First, WldS can affect the mPTP through direct action on
the pore since one of the proteins that was upregulated in WldS striatal
synaptosomes is VDAC2 [16], which has been shown to regulate the mPTP [17].
The second way that WldS can affect pore opening is suggested by our findings
that NAC and GSHEE protect against MPP+-induced loss of mitochondrial
motility. Since WldS has a similar phenotype, we hypothesize that WldS might
affect redox balance such that the pore is less likely to open and hence can
withstand various challenges in a more robust fashion. Future studies will
continue to explore this role of WldS in protecting DA axons from degeneration.

Figure 6.1 – Proposed model of how WldS protects DA axons from PD
mimetics. Modified from Toman and Fiskum, 2011 [18].
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6.2

Future Directions

6.2.1 Does disruption of the mitochondrial permeability transition pore in
DA neurons inhibit the protective effect of WldS?
We hypothesize that WldS protects DA axons by inhibiting mitochondrial
permeability transition (Fig. 6.1). To test this idea, we propose to examine if
exogenous activation of mPTP causes degeneration of DA axons and if WldS
cultures protect DA axons against this type of insult. Atractyloside (ATR)
stimulates mPTP by inducing a conformational change in the adenine nucleotide
translocator (ANT) [19]. Thus, we can utilize ATR for these experiments. We can
also test if primary midbrain cultures from cyclophilin D knockout mice [20], which
are available from Jackson Laboratories, are protected against 6-OHDA and
MPP+-induced toxicity and if this protection is similar to the WldS phenotype.
Alternatively, we could use knockdown approaches to similarly manipulate the
levels of cyclophilin D.
To determine whether delayed mPTP activation is intrinsic to WldS
mitochondria, we can also examine the effect of ATR on the m of WT and WldS
DA axonal mitochondria. If our model holds true, we predict that ATR will have
less effect on axonal degeneration and m in WldS DA axons compared to WT.
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6.2.2 Does WldS protect DA neurons through an effect on glutathione
levels?
Similar to our findings in WldS cultures, pretreatment of DA axons with the
redox-sensitive neuroprotectants NAC and GSHEE protected against MPP+induced changes in mitochondrial motility and DA neurite and cell body loss.
Thus, it is worth investigating if WldS cultures protect in a similar manner as NAC
and GSHEE by determining if WT and WldS exhibit similar levels of reduced
GSH. Reduced GSH may be visualized using Ellman's reagent or bimane
derivates such as monobromobimane [21]. Another way to measure glutathione
is through the use of redox-sensitive green fluorescent protein (roGFP) [22].
These proteins have the advantage of enabling one to quantify the glutathione
redox potential in live cells, but have the disadvantage of having poor sensitivity
and slow response to redox potential changes. An alternative approach is to
utilize the Grx1-roGFP2 fusion protein developed by Gutscher et al. [23]. Using
this fusion protein, the authors were able to measure glutathione redox potential
in different cellular compartments with high sensitivity and temporal resolution
while still allowing one to conduct experiments in live cells. More importantly this
construct, and one devised to look at thioredoxin function, can be targeted to the
mitochondria allowing redox measurements of that organelle [23].
Aside from comparing baseline levels of GSH in WT and WldS mice, we
can also examine how GSH affects the WldS phenotype by decreasing GSH
levels in WldS mice. Treatment of animals with buthionine sulphoximine (BSO),
an inhibitor of gamma-glutamylcysteine synthetase, has been shown to lower
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tissue GSH concentration [24]. If treating WldS animals with BSO abrogates their
protective effect against 6-OHDA or MPTP, this will suggest that maintenance of
GSH levels plays a role in the neuroprotective phenotype of WldS.

6.2.3 How

does

WldS

protect

against

6-OHDA-mediated

neurodegeneration?
We saw that WldS protects DA cell bodies and neurites against 6-OHDAmediated toxicity through an Nmnat-independent mechanism. However, the
exact mechanism by which WldS protects against 6-OHDA has not been fully
explored. Data from this lab has shown that ROS production from 6-OHDA
upregulates the unfolded protein response (UPR) and causes p53-dependent cell
death through two parallel pathways [25]. 6-OHDA also causes a rapid decrease
in m of DA neurons [10]. Accordingly, the following questions need to be
addressed: (1) Does WldS protect DA neurons against oxidative stress? (2) Does
WldS protect DA neurons against upregulation of UPR? (3) Does WldS protect DA
neurons against p53 activation? (4) Does WldS protect against 6-OHDAmediated decrease in m?

6.2.3.1

Does WldS protect DA neurons against oxidative stress?

Mouse embryonic fibroblasts from WldS mice were protected against
paraquat, a PD-linked toxin known to generate ROS [26]. 6-OHDA has also been
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shown to rapidly and robustly generate ROS in DA cell bodies [10], This
emphasizes the need to examine if WldS protects against 6-OHDA-mediated
increases in oxidative stress. Measuring ROS in axons can be difficult but
recently other studies have shown that MitoSox, a dye derived from DHE, has
the sensitivity to see changes in situ using optical imaging techniques. Thus,
using MitoSox, we can quantify the generation of ROS in the mitochondria of WT
and WldS DA axons in response to 6-OHDA treatment.

6.2.3.2

Does WldS protect DA neurons against upregulation of UPR?

6-OHDA causes upregulation of proteins associated with the unfolded
protein response (UPR) [27]. Since Nmnat has been suggested to have
chaperone activity [28-29], it is possible that WldS prevents 6-OHDA injury by
inhibiting the initiation of the UPR. To determine if WT and WldS cultures have
differential regulation of UPR after 6-OHDA, we can probe WT and WldS primary
midbrain cultures with antibodies for UPR markers at baseline and at the
appropriate time points after addition of 6-OHDA. Two UPR markers that would
be interesting to utilize for this purpose are ATF3, which is an early UPR maker,
and CHOP, which is a late UPR marker. If WldS has a chaperone-like activity
similar to Nmnat1, we would predict that WldS will prevent the upregulation of the
both ATF3 and CHOP.
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6.2.3.3

Does WldS protect DA neurons against activation of p53?

Our lab has recently shown that 6-OHDA-generated ROS induces DNA
damage and causes cell death through a p53-dependent mechanism.
Intriguingly, primary midbrain cultures from p53 knockout mice were almost
completely protected from 6-OHDA toxicity both at the level of the cell body and
neurites [25]. To investigate if WldS’ neuroprotective effect is potentially mediated
by p53, WT and WldS primary midbrain cultures can be stained with phospho-p53
antibody before and after 6-OHDA treatment to determine if these two types of
cultures have a similar induction of p53 activity after addition of toxin. Because
our previous work showed that DA cell bodies, but not neurites, of Puma (p53upregulated mediator of apoptosis)-null mice were protected against 6-OHDA
[25], we would predict that if WldS prevents the activation of p53, it will also
prevent the upregulation of its downstream effector, Puma.

6.2.3.4

Does WldS protect against decreased mitochondrial membrane

potential due to 6-OHDA toxicity?
Since 6-OHDA causes a rapid decrease in m in DA cell bodies [10], we
can test if WldS can prevent against changes in m from 6-OHDA injury. This
can be done in a similar manner as described in Chapter 4 and 5 in MPP +treated cultures through the use of tetramethylrhodamine ethyl ester (TMRE) as
a m indicator dye. Since we hypothesize that WldS protects axons through its
action on the mitochondria, we predict that WldS will also prevent changes in m
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axonal DA mitochondria after 6-OHDA treatment. Data from these proposed
experiments will help elucidate how WldS protects against predicted 6-OHDAinduced axonal injury.

6.2.4 Does 6-OHDA affect axonal mitochondrial dynamics?
MPP+ and 6-OHDA cause DA cell death through distinct cell death
mechanisms [10], thus what we’ve shown for MPP+ may not necessarily be the
same processes triggered by 6-OHDA toxicity. One similarity however is that, like
MPP+, 6-OHDA causes a rapid decrease in m in DA cell bodies [10]. This
implies that 6-OHDA may also cause mitochondrial dysfunction and/or
mitochondrial permeability transition. Hence, one can investigate if 6-OHDA also
causes (1) a decrease in mitochondrial motility, (2) slower anterograde
mitochondrial velocity, and (3) faster retrograde mitochondrial velocity, before
disruptions in microtubule stability are observed using the microchamber device
utilized in the experiments described in Chapter 4. We predict that 6-OHDA
effects on axon transport will overlap to a significant extent with those of MPP +.
As previously described, Burke and colleagues found that, similar to MPTP, 6OHDA also lead to depletion of striatal nerve terminals followed by retrograde
degeneration of neurons in the SN and that WldS protected against this loss of
DA terminals [30]. Thus, we predict that WldS will also protect DA mitochondria
against 6-OHDA-induced perturbations in mitochondrial dynamics.
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Taken together this will further support our hypothesis that mitochondrial
transport dysfunction leads to axonal degeneration in DA neurons. Therefore,
these data suggest that while MPP+ and 6-OHDA cause DA cell death through
distinct mechanisms, they may share a common mechanism of axonal
degeneration.

6.2.5 Does MPTP affect mitochondrial motility and velocity in vivo?
The current work shows that MPP+ decreases mitochondrial motility,
changes mitochondrial velocity, and decreases m in DA axons in vitro.
Extending results from cellular systems to in vivo systems is essential in further
establishing if MPP+-specific effects in mitochondrial health and dynamics are
integral to the role of axonal degeneration in PD pathogenesis. In vivo imaging of
the basal ganglia at the resolution needed to see individual mitochondrion is
impossible at the moment given its location deep in the animal’s brain. However,
an ex vivo approach would get us one step closer. To do this, parasagittal brain
slices can be prepared from DA/GFP mice such that DA projections from the SN
to the striatum are preserved. Protocols exist for maintaining brain slices in a
special chamber that allows for live imaging. MTR can be used to label
mitochondria and time lapse confocal imaging to monitor mitochondrial dynamics
to determine if our in vitro observations are recapitulated ex vivo. Problems with
this approach might be the excessive mitochondrial labeling seen with MTR and
the difficulty in assigning mitochondria to DA/GFP axons. Alternatively, we can
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image mitochondria by crossing DA/GFP mice with transgenic mice that express
CFP in the mitochondria (Thy1-mitoCFP-H) [31]. One caveat of this approach is
the potential difficulty of identifying the cyan fluorescence signal labeling the
mitochondria in the background of a green fluorescence signal signifying DA
axons. Another way to assess mitochondrial transport is by using static time
points in an intact animal. MTR can be stereotactically injected into either the SN
or the striatum before treating mice with an acute regimen of MPTP. Mice can
then be sacrificed at a range of time points after MPTP administration. Changes
in mitochondrial transport can be visualized by assessing differences in the
distribution of MTR distally and proximally from the site in injection, whether it is
the striatum or SN, in fixed parasagittal brain slices. Regardless of the
experimental approach utilized, we predict that mitochondrial motility and velocity
are affected by MPTP in brain slices, similar to the effect of MPP + in primary
mesencephalic cultures.

6.2.6 Does WldS protect against MPTP-induced changes in mitochondrial
motility and velocity in vivo?
As our findings on the effect of MPP+ on mitochondrial motility are seen in
vitro, we need to confirm that the protection seen in WldS axonal DA
mitochondria is replicated in vivo. We can test if WldS protects against MPTPinduced changes in mitochondrial motility and velocity in vivo by using the
method(s) described in the previous section using WldS-DA/GFP brain slices.
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Given that WldS protected axons against MPTP in vivo [1], we predict that WldS
will also protect midbrain projections to the striatum against MPTP-induced
changes in mitochondrial health and dynamics.
Our work has shed light on the role of mitochondria in MPP+-mediated DA
axonal degeneration and how WldS protects against this injury in vitro. The
results of these proposed experiments will further establish how WldS protects
DA axons against both MPTP and 6-OHDA and extend our in vitro results in vivo.
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